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resumo 
 
 
Este relatório descreve o estágio curricular em Coordenação de Ensaios 
Clínicos na Unidade de Investigação Clínica do Instituto Português de 
Oncologia do Porto Francisco Gentil, E.P.E., no âmbito do Mestrado em 
Biomedicina Farmacêutica na Universidade de Aveiro.  
Este relatório começa por descrever o Estado de Arte no Processo de 
Investigação & Desenvolvimento Farmacêutico, em especial na Oncologia, na 
Europa. São também enfatizadas tendências atuais nesta área e destacadas 
as especificidades das populações especiais e vulneráveis, relevantes no 
contexto da Investigação Clínica em Oncologia, e enquadradas no âmbito 
deste estágio. 
As atividades de coordenação de ensaios clínicos foram essencialmente 
realizadas nas Clínicas de Patologia do Pulmão, Urologia, Ginecologia, 
Pediatria, e no Serviço de Cuidados Intensivos. As atividades desenvolvidas 
tinham como objetivo principal adquirir experiência em ensaios clínicos 
oncológicos, e reforçar os conhecimentos adquiridos na minha formação 
académica. Estas atividades incluíram triagem e aleatorização de doentes, 
preparação e processamento de visitas de estudo, entrada de dados e 
resolução de questões, e gestão de documentos, entre outras atividades 
transversais aos 15 ensaios clínicos acompanhados. 
Globalmente, o estágio traduziu-se numa boa percepção das atividades 
envolvidas na realização de ensaios clínicos num hospital, e numa exposição 
valiosa ao mercado de trabalho. Também fortaleceu o conhecimento adquirido 
na minha formação académica. O estágio permitiu desenvolver competências 
e aptidões tanto no nível profissional como pessoal, tais como lidar com 
situações inesperadas, e desenvolver estratégias para ultrapassar desafios. 
Aprofundei a minha visão de profissões em investigação clínica, e espero 
continuar a enfrentar e transpor novos desafios nesta área. 
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abstract 
 
This report describes a curricular training experience in Study Coordination, 
developed at Unidade de Investigação Clínica (Clinical Research Unit) of 
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (Portuguese 
Oncology Institute-Porto), in the ambit of the Master in Pharmaceutical 
Medicine at University of Aveiro.  
This report describes the State of the Art in Pharmaceutical R&D Process in 
Europe, especially in Oncology, emphasising its current trends and stressing 
specificities of special and vulnerable populations, in the scope of the 
traineeship.  
The study coordination activities were essentially performed in the Pathology 
Clinics of Lung, Urology, Gynaecology, Paediatrics, and the Intensive Care 
Service. The activities developed had the main goal of acquiring experience in 
oncology clinical trials, while reinforcing the knowledge from my academic 
background. These activities included screening and randomisation of patients, 
preparation and processing of study visits, data entry and query resolution, and 
documents management, among other activities transversal to the 15 clinical 
trials, accompanied in the traineeship. 
Globally, the traineeship allowed a good overview of the activities involved in 
the conduction of clinical trials in a hospital, and a worthy introduction to the 
marketplace. I strengthened the knowledge acquired from my academic 
background. I developed competences and skills at the professional and 
personal level, such as dealing with unforeseen situations, and developed 
strategies to overcome challenges. I sharpened my vision of careers in clinical 
research, and hope to continue addressing new challenges in this area. 
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1. Introduction 
This report presents an overview of the activities performed as trainee in Clinical 
Studies Coordination, from September 2013 to May 2014. The traineeship took place at 
the Unidade de Investigação Clínica (Clinical Research Unit – UIC) of Instituto Português 
de Oncologia do Porto Francisco Gentil, E.P.E. (Portuguese Oncology Institute – IPO-
Porto). This curricular training is included in the Master of Science in Pharmaceutical 
Medicine of the University of Aveiro, which is affiliated to the PharmaTrain programme (1). 
This report characterises the UIC regarding its structure and organisation, as well as 
its patients’ recruitment potential for Clinical Trial (CT), and presents the objectives for this 
training at IPO-Porto. Following, it describes the State of the Art in Clinical Research and 
Development (R&D) in Europe and specifically the trends in Clinical Oncology Research. 
The activities developed during the traineeship are described in the Generic and Specific 
Training sections, the first regarding activities that contributed for the enforcement of my 
activities, namely regarding oncology CTs, and the later referring specifically to the CT 
coordination activities. This report is completed with a Discussion of the outcomes of this 
training period, regarding the main features of this experience, and a Conclusion.  
 
1.1. HOST INSTITUTION – UIC AT IPO-PORTO 
IPO-Porto is a specialised Portuguese cancer hospital institution, whose mission is to 
provide patient-oriented healthcare in time, without setting aside the prevention, 
investigation, training and, education in oncology, while ensuring high quality, humanism 
and efficiency levels (2). Professor Francisco Gentil was the major Sponsor of the first 
Portuguese cancer institution, created in 1923 in Lisbon. After that, another centre was 
created in Coimbra and, in 1974, IPO-Porto was created (3).  
During the traineeship, in April 17th of 2014, IPO-Porto has completed its 40th 
anniversary and to mark the occasion, the institution was temporarily named “Instituto 
Português de Oncologia e Esperança do Porto”, which stands for “Portuguese Institute of 
Oncology and Hope”, emphasising what the institute aims to mean to the patients (4).  
Within IPO-Porto, the UIC was created in 2006 (5) as part of the structure of the 
“Centro de Investigação do IPO-Porto” (IPO-Porto Research Centre – CI-IPOP), which 
was formally recognized by the Portuguese “Science and Technology Foundation” as a 
R&D unit in 2004 (6). CI-IPOP is a research centre for the comprehension of cancer’s 
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pathobiology mechanisms, aiming to achieve and facilitate the prevention, early 
diagnostics, prognostic assessment and, development of more effective therapies (7). CI-
IPOP is presently directed by Manuel Teixeira, MD, PhD and is organised in the UIC and 
5 Research Groups: Cancer Genetics, Cancer Epigenetics, Molecular Oncology, 
Experimental Pathology and Therapeutics, Medical Physics and Radiation Protection; (as 
shown in Figure 1) (7).  
 
Figure 1. Organogram of UIC within CI-IPOP [adapted from(8)] 
 
 
The mission of UIC is to support the conduction of CTs with investigational medicinal  
products (IMP), such as experimental medicines or medical devices, as well as non-
interventional studies (5). The UIC is coordinated by José Dinis, MD (6, 7), since 2006. Its 
goals are to attract the best worldwide CTs to the IPO-Porto, support CTs conduction and 
ensure protocol and procedures compliance (5, 9).  
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Regarding most pathologies treated at IPO-Porto, this institution is considered a 
reference centre for CTs (5, 9). The UIC showed a sustained increase of the CT’s number 
and the number of patients recruited, while reducing CTs’ implementation time, which 
increases its competitiveness and improves UIC’s performance (5). UIC supports CTs 
promoted by the pharmaceutical industry, by collaborative groups, by Investigator initiative 
and by the European Organization for Research and Treatment of Cancer (8-10). It is also 
the aim of the UIC to create a Phase I Unit in the short term (5, 10). 
 
1.1.1. Structure and Organisation 
The main action centre of a CT is the study site. The CT procedures are conducted at 
the study site, where data is generated, collected and reported, complying with the CT 
protocol. Ultimately, data gathered at all centres determine the outcome of an IMP (11). 
To comply with every CT requirements, it is crucial to have a dedicated team working at 
the research centre.  
UIC has a team that supports the participation of most clinical departments of IPO-
Porto in clinical trials. Those departments assign an Investigation Team to a given CT, as 
they are responsible for allocating the Principal Investigator (PI), Co-Investigators and 
Study Nurses to the CT (8).  
At IPO-Porto, the Investigational Team must have at least one PI, two Co-
Investigators, two Study Nurses from the Pathology Clinic where the CT is conducted, two 
Study Nurses from the Hospital de Dia (Day Care Hospital), if applicable, two 
Pharmacists, and two Study Coordinators (SCs) (8). UIC has to ensure that the CT’s team 
is properly defined (8).  
UIC supports the Investigational Team, and regulatory affairs of the CTs (8). 
Therefore, UIC is a structured and specialised team, working exclusively with Clinical 
Studies. The Organogram of UIC is presented in Figure 1. The functions of each member 
of the UIC and Investigational Team members are described on the UIC’s Internal 
Regulation, as well as Standard Operating Procedures regarding the regulatory affairs (8).  
Since the beginning of my traineeship, some of the staff functions have been re-
assigned, due to the reformulation of the team. When I started the traineeship, the 
Operational Manager was responsible for that function only. On December 2013, the 
person responsible for Operational Management resigned from IPO-Porto. To fulfil that 
role, two of the existing SCs accumulated the Operational Manager’s role since the 
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beginning of 2014: Inês Carvalho, MSc and Juliana Ferreira, BSc. Each Operational 
Manager divides her attention by different Pathology Clinics. Subsequently, this triggered 
an increased workload for both Operational Managers. To overcome that difficulty, some 
of the Operational Manager’s functions were reassigned to the Good Clinical Practice and 
Quality Manager (12, 13). Furthermore, a new role—Clinical Trial Assistant (CTA)—had 
already been created in September 2013, to assist the SCs on their tasks. Some of the 
administrative functions were also allocated to the CTA’s role. The teams’ members and 
their respective updated roles are described below (8): 
• Investigational Team 
Principal Investigator: Evaluates the proposed CT and financial protocol; defines the CT’s 
team; cooperates in the CT’s submission and approval process; complies with the 
protocol and regulations; informs and obtains patient’s Informed Consent; records and 
notifies Adverse Events (AE); keeps the patients’ Personal Health Records (PHRs) up to 
date; and ensures confidentiality and medical assistance to the participants.  
Co-Investigator: Has the same role as the PI, regarding the aspects related to the CT 
conduction. Also, the Co-Investigator has to inform the PI/SC if there is a non-compliance 
situation. 
Study Nurse: Performs every nursing CT procedures defined in the protocol, such as: 
evaluate and record clinical data; prepare and administrate IMPs; explain its instructions 
to the participant; drug accountability; inform the Investigator of non-compliance 
situations; collect, process and send biological samples according to protocol; and verify 
questionnaires completion. 
• Pharmaceutical Services  
Pharmacists: Performs every pharmaceutical procedures defined in the protocol (8). 
• CI-IPOP  
Financial Assessor: Evaluates, reviews and emits a Financial Opinion regarding the CTs’ 
Financial Protocols; prepares the distribution proposal of the financial compensations; and 
complies with the procedures for compensation of CT participants’ expenses, in 
accordance with the protocol. 
Financial Assistant: Assists the Financial Assessor on his/her activities. 
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• UIC 
UIC Responsible: Represents IPO-Porto externally and technically assists the 
Administration Board on CTs matters; ensures the communication with the several 
departments and services of IPO-Porto involved in CTs; evaluates the operational and 
scientific feasibility of CTs; approves the financial proposals; evaluates the educational 
needs of the team’s elements and their performance. 
Good Clinical Practice and Quality Manager: Proposes, develops and maintains the Good 
Clinical Practice (GCP) System; performs Internal Audits and participates in the support 
team to the external audits and inspections; maintains the records of the quality 
documents necessary to CTs conduction, in coordination with the several departments 
and services of IPO-Porto; prepares, submits and accompany the “Dossier of Approval 
Request for the conduct of a CT at IPO-Porto”; receives and fast-forwards the “Feasibility 
Questionnaires” of new CTs, and maintains its record and their respective response times; 
reviews the records of CTs procedures done to each participant and informs the Financial 
Assessor, to allow the billing to the Sponsor. 
Operational Manager: Manages UIC’s daily activities and coordinates the activities of 
each UIC member; prepares and participates on the team of support to internal and 
external audits and inspections; participates in the evaluation of the employees 
performance; coordinates, with entities external to IPO-Porto, the conduct of 
complementary diagnostic exams required by the CT protocols; manages reclamations 
and conflicts, CT protocols deviations, and notifies the Sponsor. 
Study Coordinator: Implements CTs, supporting the CT team in all activities related with 
the preparation and organization of the procedures and documentation; schedules and 
gives support to the monitoring visits; participates in Investigators meetings; participates in 
site initiation visits; ensures that the CT team complies with the GCP and with the CT 
protocol; informs the Operational Manager of the protocol deviations; reviews the PHRs, 
ensures that the information necessary to fill the Case Report Forms (CRFs) is complete 
and up-to-date and, completes the CRFs accordingly and on time; supports the 
investigators in queries resolution and in reporting Serious Adverse Events (SAE) to the 
Sponsor; maintains the CT procedures registry updated; complies with the procedure 
respective to the compensation of CT participants’ expenses, according to the protocol; 
updates the information about each CT status, reporting the CT status internally and to 
the Sponsor. 
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Clinical Trial Assistant: Assists the SC on his/her activities, namely the archive of 
documents and its update, and scheduling the participants’ visits and exams (and 
verifying the agenda); process the participants’ expenses and prepare its reimbursement; 
maintains the essential CT documentation up-to-date and archived, complying with the 
Sponsor procedures; participates in site initiation visits; supports the completion of Quality 
of Life Questionnaires by the participant; and receives any external elements to the IPO-
Porto. 
Administrative: Supports the UIC on every activity related with CTs, namely the 
preparation and internal distribution of CTs documentation and material; receives and 
distributes every correspondence and CTs materials in the UIC, and dispatches 
necessary material to the exterior. 
Operational Assistant: Controls and ensures the availability of the material necessary to 
the UIC functioning; manages the PHRs of the participants; distributes and collects CTs’ 
material as needed within IPO-Porto; distributes mailing; and articulates the distribution of 
the Monitoring Offices with the SCs, according to the monitoring visits agenda and 
prepares them for each visit with the adequate material. 
At UIC, there is one UIC Responsible, one GCP and Quality Manager, two Operational 
Managers, five SCs, three CTAs (one of them also accumulating administrative functions), 
and two Operational Assistants. Each SC has a Pathology Clinic assigned (8). The 
Pathology Clinics that have a specific SC associated are: Urology; Gynaecology; Lung; 
Paediatrics; Soft Tissue and Skin; Endocrine Tumour; Head and Neck; Breast; Onco-
Haematology; and Digestive. The Services with an assigned SC are: the Intensive Care 
Service; and the Bone Marrow Transplantation Service. 
The Soft Tissue and Skin, Head and Neck, Endocrine Tumour, and Breast Clinics are 
assigned to one SC. The Onco-Haematology Clinic and Bone Marrow Transplantation 
Service are associated to a SC. Given the workload of the aforementioned clinics, some 
of the CTs of the Breast and Onco-Haematology Clinics are the responsibility of another 
SC, whom accumulates CTs of both clinics. The Digestive Clinic is associated to another 
SC. The Clinics of Urology, Gynaecology, Lung, Paediatrics, and Intensive Care Service 
are assigned to another SC, whom I accompanied.  
Given the confidentiality issues associated with the conduction of CTs, UIC’s facilities 
are of controlled access (8, 9). Only the UIC members have permanent access to the 
facilities. Members of the CTs teams have temporary access to UIC’s facilities, as well as 
external elements to IPO, such as Clinical Research Associates (CRAs) or auditors. A 
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plant of the UIC’s facilities can be encountered in the UIC’s internal regulation (8) and also 
in (14), in page 5. 
 
1.1.2. Recruitment at IPO-Porto  
UIC has shown a sustained growth of the recruitment rate in the last years (9), as 
shown in Figure 2.  
 
Figure 2. Recruitment Rate at IPO-Porto from 2010 to 2013 [adapted from (15)] 
 
 
 
 
 
 
 
 
In 2010, 76% of the recruited patients were randomised (Figure 2). This means that 
25% of the patients recruited (Figure 2) were screening failures. In 2011 and 2012, the 
recruitment increased steadily. However, 65% of the patients were randomised, which 
means a higher screening failure rate, despite the efforts to include more patients in CTs. 
It is important to clarify that the number of screening failures does not depend on the 
centre, since many patients enter CTs, perform the exams necessary to confirm eligibility 
but the exams’ results do not comply with the selection criteria and, therefore, are not 
randomised.  
If we look alone at the number of randomised patients since 2010, it has increased. 
The percentage of patients randomised versus patients recruited, in 2013, increased to 
73%, which translates the effort of randomising patients at IPO-Porto, by increasing the 
recruitment numbers  (Figure 2).  
Thus, IPO-Porto has great potential of increasing its recruitment and number of 
patients participating actively in a CT. 
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1.2. OBJECTIVES  
This section presents my objectives at UIC, as a trainee. The primary objectives 
represent the aspects I considered necessary to achieve a proper training and consider 
myself a professional of clinical research. The secondary objectives represent specific 
aspects I would like to develop or acknowledge, in the context of an investigation centre. 
 
1.2.1. Primary Objectives 
The main objectives were to: 
• develop skills and gain experience in Study Coordination;  
• reinforce and apply the knowledge acquired in the BSc and MSc; 
• have a perspective of the working environment; 
• understand the functioning of a clinical research centre. 
 
1.2.2. Secondary Objectives 
The secondary objectives were to: 
• perform the daily activities of a SC on-the-job and in time; 
• understand the communications’ flow in a clinical research centre; 
• to acknowledge the CTs’ patients circuit within IPO-Porto; 
• acquire the necessary knowledge to complete CRF’s; 
• contribute to the development of internal and/or external documents and 
understand its relevance in a clinical research centre; 
• obtain an overview of the daily activities of GCP and Quality Management; 
• understand the conduction and preparation of an audit; 
• improve my communicational skills and practice medical writing skills. 
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1.3. STATE OF THE ART IN ONCOLOGY AND PHARMACEUTICAL R&D 
PROCESS IN EUROPE 
This section presents an overview of the current situation of the Pharmaceutical R&D 
and oncology research processes, and an overview of the CTs’ Classification. Also, it 
briefly describes the state and particularities of the Oncology Clinical Research, referring 
considerations about special populations, that are a reality in the daily context of activities 
in Oncology Clinical Research. 
 
1.3.1. Current concepts of the Pharmaceutical R&D Process  
Biopharmaceutical research has provided new treatments, and potentiated by 
knowledge and technology, mortality has been reduced and the quality of life has been 
increased (16, 17). People now live longer and healthier, due to the wide availability and 
accessibility of treatments. However, there are  pathologies that still entail great 
challenges to the R&D process, such as some type of cancers and orphan diseases (16, 
17). In addition, the current process of Pharmaceutical R&D is considered unsustainable 
(18, 19), thus its paradigm is being changed, to continue delivering innovative medicines 
(18, 19).  
R&D expenditure has increased, due to the high attrition rates, the cost of larger CTs, 
and the volume of resources required to get approval by regulatory authorities (16). 
Before a new chemical entity shows results proving failure, it usually reaches an 
advanced stage of research (16). Also, many medicinal products enter research, and few 
become a marketable product (Figure 3), increasing the attrition rates (17), due to the 
weak predictability of safety and efficacy (20). One of the reasons to the lack of efficacy in 
some therapeutic areas is the unpredictable results from animal models, i.e., non-
correspondence between the effects obtained in animal models and those obtained in 
humans, leading to higher failure rates in Phase II and III trials (20). A huge investment is 
done, in order to develop one valid product. Besides, the R&D process is extremely slow 
(Figure 3): it is estimated that a product takes about 12 to 13 years to enter the market 
(17, 18). 
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Figure 3. Pharmaceutical R&D process timings and success estimates (18) 
 
Before an IMP enters the clinical development phase, it is estimated that it passes the 
pre-discovery and discovery phases, when 5,000 to 10,000 compounds are screened. 
Most of those compounds are eliminated and about 250 are selected for the preclinical 
phase (non-clinical phase, conducted in vivo) (18). Up to this point, 3 to 6 years have 
passed. Of the preclinical tests, 5 IMPs are selected and submitted as an Investigational 
New Drug, entering phase I CTs (18). The CTs may take up to 6 to 7 years, until a New 
Drug Application is submitted. Only 1 IMP receives approval, and 9 to 13 years may have 
passed (18). Furthermore, general population may have access to the new drug only 0.5 
to 2 years after its approval (18). The failures related to efficacy and safety issues redirect 
to the need of changing the R&D paradigm, through the development of more predictive 
models and proof of concept earlier in development, delivering innovation to unmet 
medical needs (21, 22).  
The new R&D paradigm exposes the need for a dynamic new strategy. Its goal is to 
obtain profound knowledge of the pathophysiology of the condition in study. This brings 
more confidence in the mechanism of action and safety, thus allowing a quicker 
progression of the R&D process (23). The use of bioinformatics, better evaluation tools, 
and knowledge management, are crucial requirements to the success of this promising 
new approach (21, 22).  
In this ambit, it is important to understand how clinical drug development has been 
divided until now. This division is conventional, and classifies CTs in four temporal phases 
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(Phase I-IV). The results from each phase have been used to determine the design of the 
next phase (24). However, with the evolution of CTs, that classification is no longer 
accurate, since the same type of CT may occur in different temporal phases of the clinical 
development, with the conduction of adaptive CTs. Thus, a classification system based in 
study objectives is more adequate. The relation between these two classification systems 
is represented in Figure 4, and shows the overlap of the study types and temporal phases 
(25).  
 
Figure 4. Different development phases and types of clinical studies (25)  
The CT phases, objective and related study population are described in Table 1, with 
the commonly associated temporal phase. 
 
Table 1. CT Phases objectives [adapted from (24, 25)] 
Phase Objectives Study population 
Human 
Pharmacology 
Phase I 
 
To evaluate tolerability, safety, define pharmacokinetics and 
pharmacodynamics; explore drug metabolism and drug 
interactions and; estimate activity (24, 25).  
Limited number of 
healthy volunteers; 
Patients if there are 
toxicity limitations, such 
as in cancer diseases 
(24, 25). 
Therapeutic 
Exploratory 
Phase II 
Phase IIa: To assess pharmacodynamics, pharmacokinetics 
and; dose–response relationships (24).  
Phase IIb: To evaluate the dose–response relationship, 
increasing the understanding of efficacy, safety and tolerability 
of the IMP (24).  
Small numbers of 
patients with the disease 
under study (24) 
Therapeutic 
Confirmatory 
Phase III 
To confirm efficacy, safety profile; explore the dose–response 
relationship, and adequate basis for assessing the benefit–risk 
relationship to support marketing authorisation (25); allow the 
completion of the official product information (25). 
Hundreds or thousands 
of patients, usually an 
international programme 
(24) 
Therapeutic 
Use  
Phase IV 
To refine dosing recommendations; identify less common AEs; 
monitor safety aspects or compare the drug with other 
therapies already on the market (25); broaden experience in 
every-day clinical practice (24). 
Patients, with wider 
selection criteria (24) 
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To achieve the reformulation of the biopharmaceutical sector, a common effort must 
be carried between industry and academy, on the pre-competitive research phase, 
concerning the globalization of knowledge, which will lead to innovative new therapies (19, 
22).  
1.3.2. Current European R&D Process 
There is currently an European initiative coordinated by both pharmaceutical industry 
and regulators, aiming to modernize the current R&D paradigm: the Innovative Medicines 
Initiative (IMI), existing since 2008. The first IMI Scientific Research Agenda, published in 
2008, had four research pillars: Safety; Efficacy; Knowledge Management; and Education 
and Training. As these pillars were broad, the revised IMI Scientific Research Agenda of 
2011 replaced them with 7 focused Areas of Research Interest (19, 22): 
1. The Patient in the Focus of Research: Development of drug research 
programmes focussed on the needs of the patients, with targeted outcome measures, and 
the participation of patient groups in consortia and development of partnerships (19, 22). 
2. Diseases – Drug Efficacy: Development of new methods for evaluation and 
enhance of drug efficacy. Target the delivery of therapies, improvement of patient 
compliance, and generation of observational data earlier in drug development (19, 22). 
3. Knowledge and Knowledge Management: Management of the knowledge 
generated globally, for ensuring the effective integration of data and maximisation of 
resources. Generation of knowledge, through the correlation of in vivo, in vitro and in silico 
research, while maintaining the sustainability of the databases (19, 22). 
4. Strategies in R&D: Reduction of the attrition rate, through the modern ‘omics’-
focussed research combined with systems biology, leading to better understanding of the 
diseases aetiology (19, 22). 
5. Drug Development and the Regulatory Framework: Development of evaluation 
and qualification tools and technologies for regulatory use. Addressing of challenges 
regarding chemical and formulation technology, in the context of regulatory aspects (19, 
22). 
6. Tools and Techniques: Identification, qualification and implementation of the tools 
and techniques developed for efficient R&D process (19, 22). 
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7. Education and Training: Science Communication: Spreading education and 
training, for reinforcing the position of the European scientific community in global R&D 
(19, 22). 
In 2014, a Strategic Research Agenda for Innovative Medicines Initiative 2 (IMI2) has 
been published (18). The IMI2 agenda shapes the major challenges in the European 
healthcare system, pharmaceutical industry and the regulatory framework. In the IMI2 
agenda, specific projects were not defined. Instead, strategies were identified and its 
adoption will lead to the creation of focussed and balanced projects (18).  
The major goal of the IMI2 agenda is to deliver the background to start collaborative 
projects, allowing to approach and/or resolve bottlenecks on the delivery of effective and 
efficient healthcare to patients (18). The delivery of innovative solutions requires the union 
of know-how of academia, large and mid-size pharmaceutical and biotech companies, 
patient organizations, regulators, and health authorities and health technology agencies 
with the common goal of reforming and improving the current healthcare system (18).  
The IMI2 defined 4 major axes of research, emphasising scientific challenges in which 
the collaboration of multidisciplinary stakeholders is crucial for success (18). The 
objectives/challenges of these 4 axes are described below. 
Axis 1: Target validation and biomarker research (efficacy and safety)  
To achieve better understanding of the pathophysiologic mechanisms, AEs, and the 
factors conditioning patients’ individual responses to medicinal products. This will allow to 
obtain the knowledge and tools necessary to maximise the benefit of the treatment for the 
patient (18). 
Axis 2: Adoption of innovative clinical trial paradigms 
To sharpen up the concept of adaptive CT design, to minimise uncertainty in real 
world benefit/risk assessments of the new medicinal products, and to balance the need of 
data collection, regarding potential AEs (18). Also, to create more preventive approaches, 
and access of patients to medicinal products. 
Axis 3: Innovative Medicines 
To invest in strategies for early diagnosis and prevention, once there is an increasing 
incidence of chronic diseases and elderly population. There is now the goal of integrating 
therapies with prevention and healthy life style choices, and patients’ education on health 
and their individual risk factors, to reduce the burden of diseases in society. Thus, there is 
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the need of the identification and each patient’s risks and respective required intervention, 
minimising the occurrence of AEs (18). 
Axis 4: Patient tailored adherence programmes 
To study patients’ life style, behavioural, societal and environmental factors, for the 
development of programmes, to maximise positive health outcomes and enhance drug 
adherence (18). This goal will take advantage of the new mobile technologies, 
customising intervention for individual patients (18). 
The 4 axes of IMI2 are summarised in Figure 5, presenting its action areas for the 
progress of R&D. 
 
Figure 5. Integration of IMI2 Strategies in 4 Axes of research (18) 
 
Each of these axes clearly identifies core objectives in the IMI2 Strategic Research 
Agenda to overcome challenges and achieve its goals. The aim and vision of IMI2 is “The 
right prevention and treatment for the right patient at the right time” (18) (Figure 6), as a 
continuation and progress of the IMI1. IMI2 pretends the delivery of effective and 
integrated healthcare solutions for priority medicines (18). For this matter, IMI2 will 
establish a partnership with ongoing initiatives, creating cross-disciplinary, international 
research (18).  
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Figure 6. IMI 2 summary: “The right drug to the right patient at the right time” (18) 
 
 
1.3.3. Trends in Clinical Oncology Research 
Regarding the anticancer drug development there is a high failure rate that needs to 
be addressed (26). It is estimated that about 95% of all IMPs tested in Phase I CTs fail to 
reach a marketing authorisation (26). Acting as predictors of success in CTs, new 
preclinical models can help reducing the attrition rate of new anticancer IMPs. Regarding 
the development phase, CTs should integrate predictive and pharmacodynamic 
biomarkers, driven by tumour biology. In the field of anticancer R&D, there is also the 
strong need of improving the collaboration between industry, academia and regulators, in 
order to meet the requirements of all stakeholders (26).  
According to IMI2 Strategic Research Agenda (18), the prevalence of cancer diseases 
implies a considerable weight to the healthcare systems. Cancer patients need regular 
checkups and need to be medically followed for long-term conditions (18). The evolution 
of medical care, through diagnosis and treatment of cancer diseases, led to the increase 
of patients living with cancer. This, combined with the ageing of the population and risk 
factors such as exposure to tobacco smoke, lack of physical exercise and poor diet, 
triggers the increase of the incidence of cancer, which is expected to increase by 60 % 
over the next decade (18). European trends will be the aim of the following 
characterisation.  
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A recent article in the European Journal of Cancer (27), estimated, in Europe, in 2012, 
a value of 3.45 million new cases of cancer (excluding non-melanoma skin cancer) and 
1.75 million deaths from cancer (27). Female breast, colorectal, prostate and lung cancers 
are the most common in Europe, and represent half of the overall burden of cancer (27). 
Lung cancer is the cancer with highest mortality in men, while breast cancer is the cancer 
with highest mortality in women (27-29). However, it is estimated that this is changing for 
women: lung cancer may become the cancer with highest mortality for both genres, as 
lung cancer mortality is predicted to increase in women, while breast cancer mortality rate 
is predicted to decrease (28, 29).  
As patients live now longer with cancer, the type of medicines needed has to equally 
evolve. There is now the need of assessing the benefit/risk relationship of the long term 
use of therapies (18). Also, there is the need for new biomarkers development for early 
diagnosis, and target therapies (18).  
Oncology deals with many different cancers, which are genetically distinct. Each 
cancer responds to treatment combinations differently (30), and therapies for cancers 
diseases are complex, and often toxic (31). Cancers involve AEs caused by the disease 
and/or treatment, and frequently are associated with relevant co-morbidities (31).  
Thus, oncology CTs may have innovative study designs, with exhaustive eligibility 
criteria, complex randomisation schemes and comprehensive treatment requirements, as 
well as AEs management specificities (31). The ideal investigational protocol in oncology 
should be flexible enough to adapt to patients’ needs (31) (as sought by the personalised 
medicine area). These improvements in oncology R&D require the overcome of 
challenges regarding the regulatory approval of these therapies, as well as a thorough 
pharmacoeconomic assessment of these new technologies (18).  
Furthermore, as reinforced in the IMI2, there is the need of constructing a platform that 
promotes and structures collaboration between all life sciences professionals and fronts, 
to achieve the common goal of finding “the right prevention and treatment for the right 
patient at the right time” (18, 32). This goal would benefit from the gathering of patients’ 
tumour samples to characterise the molecular level of cancer diseases, allowing the 
improvement of diagnostic and statistical tests and the development of target agents for 
identifying molecular alterations (18). To overcome these challenges, a common effort has 
to be done between industry, hospitals, and academy, to maximise the use of the existing 
resources. 
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Regarding the contribution of CTs to the progress of oncology research, there is 
currently a consortium, the EurocanPlatform, aiming to use CTs and biorepositories data 
of patients, incorporating at the same time new imaging technologies for describing and 
characterising the tumours and treatment effects (18). Applying the IMI2 research axes to 
oncology, the following needs/objectives were specified, per applicable axis:  
For Axis 1 - Target validation and biomarker research (efficacy and safety), the main 
aims are the: a) Reclassification of tumours on the molecular level; b) Identification of 
molecular targets in tumour formation; c) Integration of genetic analysis and tumour 
biology with bioinformatics and systems biology approaches to identify novel targets; d) 
Validated pharmacologically to accelerate drug development; e) High quality biomarker 
assays; f) Better understanding of histology-based and molecular-based tumour types and 
agree a standard of evidence to extend use of new medicines into other histology in 
patients with the same mutation (18). 
For Axis 2 - Adoption of innovative clinical trial paradigms, the main aims are the: a) 
Validation of progression as a surrogate marker and analyse overall survival adjusting for 
unavoidable confounding factors; b) Agreeing on acceptable primary endpoint criteria for 
oncology CTs when overall survival is not a feasible endpoint; c) Development of markers 
of AEs with sufficient sensitivity and accuracy to support benefit/risk assessment; d) Better 
understanding of how the individual patient assesses the benefit/risk equation; e) 
Implementation of the new “Medicines Adaptive Pathways to Patients” initiative when 
applicable, to accelerate access to new treatments for unmet medical needs; f) Validated 
statistical methods for providing high quality results from post-marketing CT; g) 
Harmonization of trial procedures across Europe; h) Establish collaborative multicentre 
screening platforms, increasing efficiency of recruitment (18, 32). 
For Axis 4 - Patient tailored adherence programmes, the main aims are the: a) 
Building of the outcomes of the “Pharmacoepidemiological Research on Outcomes of 
Therapeutics by a European Consortium” project to communicate the state of science and 
benefit/risk of new medicines to the patient in a common language; b) Development of 
approaches integrating prevention, early detection, susceptibility, and lifestyle changes; c) 
Establishment of continuous patient screening strategies combined with early CTs; d) 
Continue the early identification of relevant premalignant and malignant lesions, allowing 
chemoprevention  (18). 
Summarising, some of the current main challenges in oncology R&D are to obtain 
tools and competencies needed to support precision medicine approaches, pairing with 
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the required regulatory framework, an improved early detection and management of 
disease, and new therapeutic options personalised to tumour type, lifestyle and genetic 
susceptibility. 
 
1.3.4. Special and vulnerable populations in CTs 
“Some groups in the general population may require special contingencies because 
they have unique risk/benefit considerations that need to be taken into account during 
drug development, or because they can be anticipated to need modification of use of the 
dose or schedule of a drug compared to general adult use. Pharmacokinetic studies in 
patients with renal and hepatic dysfunction are important to assess the impact of 
potentially altered drug metabolism or excretion.”, according to (25). Also, there is the 
need for specific ethical considerations related to the consent from vulnerable populations 
and the compliance with the specific procedures regarding vulnerable subjects (25).  
Several special populations can be identified: Pregnant women, nursing woman, children, 
geriatric patients, and patients from different ethnic groups (25).  
Geriatric population frequently has associated comorbidities, and concomitant 
therapies increasing the risk of drug interactions (33). Therefore, it is crucial to have 
information about a medicinal product activity in the elderly (33). 
Paediatric population require several considerations regarding CTs. Medicinal 
products developed for adults do not allow a correct inference of its activity in paediatric 
patients, even if its dose is adjusted. Thus, if a condition is anticipated to possibly occur in 
the paediatric population, a Paediatric Investigation Plan should be developed for that 
condition’s treatment (34). Regarding CTs in children, special actions are taken, such as 
the minimisation of risk and distress (for example, reducing discomfort in invasive 
procedures through the use of local anaesthetics) (34). CTs in this population ensures that 
the patients have access to medicines appropriately formulated and evaluated for their 
use (34). 
A type of patient considered to be vulnerable is a subject whose willingness to 
participate in a CT may be influenced by the expectation of benefits or a retaliatory 
response, from senior members of a hierarchy, depending on his/her answer (35). 
According to (35), an example may be a subject that is member of a group with a 
hierarchical structure, such as health students, subordinate hospital and laboratory 
personnel, employees of the pharmaceutical industry, members of the armed forces, and 
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prisoners. In addition, vulnerable patients may also be those with incurable diseases, in 
nursing homes, unemployed or impoverished persons, in emergency situations, belonging 
to ethnic minority groups, homeless, refugees, minors, and incapable of giving consent 
(35). 
Special/vulnerable populations are a reality at IPO-Porto. These populations may also 
participate in a CT.  An example is the paediatrics population (36), the geriatric, and 
vulnerable population.  
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2. Training activities 
The traineeship at UIC can be divided into Generic Training and Specific Training. The 
generic training consisted in understanding aspects which are intrinsic and transversal to 
the study coordination daily routine and that are considered basic knowledge for 
performing study coordination in oncology. The specific training section describes the 
activities I performed as SC trainee at UIC, firstly without being associated to a specific 
clinic, and afterwards while being associate to the Pathology Clinics of Gynaecology, 
Lung, Paediatrics, Urology, and the Service of Intensive Care. 
 
2.1. GENERIC TRAINING 
As a SC trainee, I was already aware of the regulatory affairs regarding the Clinical 
Investigation applicable laws and regulations, and the submission process and approval of 
a CT. Activities conducted before the CT’s approval will also be described in this section. 
Furthermore, I developed knowledge in specific classification systems, widely used on 
CTs performed at IPO-Porto. I also acquired skills and experience in web based 
Informatics Systems necessary to perform Electronic Data Capture and, Interactive 
Response Systems. This generic knowledge is described in the following sections. 
 
2.1.1. Regulatory Affairs 
The regulatory activities are not part of a SC’s daily routine at UIC, as they are 
performed by the GCP and Quality Manager. However, in order to be able to properly 
perform the study coordination activities, I had to be aware of the applicable guidelines 
and regulations, and acquired training in GCP. 
2.1.1.1. Legislation 
The Clinical Investigation area is highly regulated. My traineeship did not involve 
acquiring knowledge of the applicable legislation. However, the regulatory affairs 
knowledge that is part of my academic background was remembered during the 
traineeship.  
CTs on a medicinal product for Human use are currently regulated by the National 
Law “Lei n.º 46/2004, de 19 de agosto”, based on Commission Directive 2001/20/EC, of 
April 4th and Commission Directive 2007/47/EC of 5 September 2007, the latest 
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concerning Medical Devices. The Directive 2001/20/EC of the European Parliament and 
of the Council of 4 April 2001 establishes specific provisions regarding the conduct of CTs 
on human subjects involving medicinal products, relating to the implementation of GCP. 
This Directive does not apply to non-interventional trials. 
During my traineeship, a new law in clinical investigation was published in Portugal—
“Lei n.º 21/2014 de 16 de abril” (37)—and will be in force in June 2014. The new clinical 
investigation law will supersede the aforementioned “Lei n.º 46/2004, de 19 de agosto”.  
The main aspects changed in the new law are that it adds considerations about non-
interventional CTs; creates the National Registry of CTs to facilitate submissions and 
make clinical investigation transparent; creates the National Network of Health Ethics 
Commissions to harmonise their evaluation; establishes competitive deadlines in the 
evaluation of CTs at the Comissão de Ética para a Investigação Clínica (National Ethics 
Committee for Clinical Research – CEIC)—30 days—and approval of CTs at Autoridade 
Nacional do Medicamento e Produtos de Saúde, I. P (National Competent Authority for 
Medicines and Health Products – INFARMED)—30 days; establishes a deadline for the 
Comissão Nacional de Protecção de Dados (National Commission of Data Protection – 
CNPD) approval—30 days; establishes deadlines for financial contract analysis at CTs 
sites—15 days. 
The Commission Directive 2005/28/EC of 8 April 2005 lays down the principles and 
detailed guidelines for GCP as regards IMPs for human use, as well as the requirements 
for authorisation of the manufacturing or importation of such products. This directive was 
transposed to the national decree-law “Decreto-Lei n.º 102/2007, de 2 de Abril”. 
In addition, “Portaria n.º 57/2005 de 20 de Janeiro” approves the functioning of CEIC, 
which ensures protection of participants’ rights, safety and well-being during CTs. CEIC 
also does a previous evaluation and monitoring of all clinical trials on a medicinal product 
for Human use. CEIC assesses the relevance and design of the research protocol, the 
benefit-risk evaluation of the intervention, human resources and materials available in 
research centres, financial concerns, recruitment procedures, the procedure for obtaining 
informed consent, and the circuit and accessibility of the experimental drug.  
CNDP is regulated the national law “Lei 67/98, de 26 de Outubro”, and establishes 
guiding principles of the processing of personal data. CNPD deliberates data protection 
aspects of participants in CTs on its deliberation “Deliberação nº 333 / 2007”. CNPD 
ensures the consent of the participants, as well as confidentiality concerns. The 
aforementioned laws are the essential for CTs conduction in Portugal. 
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2.1.1.2. Feasibility Questionnaires 
The feasibility questionnaire is a document sent by the Sponsor to a specific e-mail for 
clinical studies (managed by UIC) (8). The questionnaire is answered by the appointed 
Medical Oncologist of the applicable Pathology Clinic. This document assesses the site’s 
conditions to perform a CT. It asks about the site equipment (for example, refrigerator with 
adequate characteristics to keep biological samples), about the human resources 
availability, the recruitment potential, certification, and other issues that may apply. This 
document usually has up to a 5-day answering period, and a record of all feasibility 
questionnaires answered at IPO-Porto and respective answer date is kept by the UIC (8). 
An example of a feasibility questionnaire can be found at (38). If required by the Sponsor, 
a pre-trial qualification visit can be performed at IPO-Porto, to assess the conditions. 
I received an informal lecture about this subject, performed by Joana Maia, PharmD, 
GCP and Quality Manager of UIC. During this lecture, I understood the UIC’s intervention 
in feasibility questionnaires forwarding, and the importance of a timely answer and the 
characteristics a centre should have for its selection. 
2.1.1.3. Clinical Trial Approval  
First of all, the Sponsor confirms that IPO-Porto will participate in the CT, and sends a 
summary of the CT to the UIC. The summary is forwarded to the Medical Oncology 
Coordinator of the Pathology Clinic and to the Director of Service, to the Pharmaceutical 
Services, Day Care Hospital, and other applicable Services (such as Cardiology for ECGs 
or Nuclear Medicine for Bone scans). If the Medical Oncology Coordinator of the 
Pathology Clinic and the Director of Service have a favourable opinion on the proposed 
CT, a PI for the CT is suggested to the UIC. The UIC Responsible also emits an opinion 
and, if favourable, the PI is contacted to be informed about the summary of the CT and to 
decide about his/her participation. This has to be done in 5 working days (8). The Director 
of Service, the Pharmaceutical Services, the Day Care Hospital, and other applicable 
Services also emit an opinion and, if favourable, propose the elements that will be part of 
the CT team and inform the UIC. The PI proposes the CT team elements of his/her 
Pathology Clinic. The CT team is defined, and approved by the PI and the Responsible of 
UIC. This has to be done in 5 working days and the CT team is sent to the Sponsor (8).  
After that, the PI fills the CT Submission Form, which is an internal document of IPO-
Porto, containing the CT team, estimated costs and the aforementioned intervenients’ 
opinion. This document is part of the submission dossier.  
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The GCP and Quality Manager verifies if the submission process contains all the 
mandatory documents required by IPO-Porto Administration Board and listed in (8), as 
well as study documents stated in the Sponsor’s list of sent documents. It is also 
important to do quality control in this process. The GCP and Quality Manager also verifies 
if all the documents’ versions are correct, as well as other regulatory data. The GCP and 
Quality Manager obtains a financial opinion from the Financial Assessor of CI-IPOP and 
approval from the AB. At IPO-Porto, the AB receives and verifies the submission process 
as soon as possible. This means that a CT may be ready for final approval at IPO-Porto 
even before it was approved by INFARMED and CNPD, or evaluated by CEIC, increasing 
IPO-Porto competitiveness as a clinical research centre. Instead of the final 
approval/evaluation documents, the Administration Board evaluates the submission 
dossier with a document confirming the CT submission to authorities. In this particular 
situation, when a CT is approved by the national authorities, the final documents are 
added to the submission process, and the CT becomes officially approved at IPO-Porto. 
The essential documents for conducting a CT are listed in (35).  
Concerning other documents, the CT Contract is approved by the Administration 
Board after evaluation of the Responsible of UIC and the PI. The Financial Contract is 
evaluated by the Financial Assessor of CI-IPOP and the Responsible of UIC. 
I received an informal lecture about the Submission Process, performed by Joana 
Maia, PharmD, GCP and Quality Manager of UIC. During this lecture, I understood the 
UIC’s intervention in submission processes, and the role of the Administration Board in its 
approval. 
2.1.1.4. Guidelines 
The Declaration of Helsinki is a very important document, and states the core of CTs: 
The patient should never be harmed in any way in favour of public health or society (39). 
During the traineeship, a new version of the Helsinki Declaration was published, with a 
new organisation of its structure (39). Being a world reference, the 2013 Declaration of 
Helsinki replaces the previous versions of the declaration, having clarified the patients’ 
protection in the conduct of CTs (39). The main changes of the 2013 declaration are that: 
• there should be a risk minimisation and continued monitoring and assessment 
while the study in ongoing (39);  
• subjects should be compensated appropriately of harm caused by the 
participation in a CT (39);  
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• the patients should always receive the best available intervention when not in 
the IMP study arm (39); 
• the placebo use should be well justified, and only if there is the need to 
determine the safety or efficacy of an intervention, there is no active treatment 
available, or if it is proven that the subjects will not be harmed in any way by 
not receiving the treatment (39);  
• the patients that benefit from the CT intervention and still need it after the trial, 
should have access to it, and this information should be disclosed in the 
Informed Consent Form (ICF) (39). 
The “International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use” (ICH) makes recommendations towards 
harmonising the interpretation and application of technical guidelines and requirements for 
pharmaceutical product registration (40). This harmonisation is achieved through the 
development of ICH Guidelines (40).  
One of the most important guidelines when conducting a CT—the ICH E8 Guideline—
addresses General Considerations for CTs. Additionally, a crucial document is the ICH E6 
Guideline on GCP, which establishes principles to be followed in the conduct of CTs, 
improving Clinical Research.  
Other important guidelines to be aware of, in oncology CTs, are those with 
considerations based on agreed ethical and scientific principles, for clinical testing 
programs conducted in special populations, such as ICH E7 for geriatric populations (33), 
and E11 for children (34).  
During my training in study coordination, I remembered the concepts and 
specifications of these guidelines that I already had present from my academic 
background.  
 
2.1.2. Good Clinical Practice 
The GCP training is an essential requirement to perform Study Coordination activities. 
Thus, as a SC trainee, I did an online training in GCP, where I reviewed the knowledge 
acquired in the MSc course, and acquired a certificate in ICH-GCP (E6 Guideline). The 
GCP guideline is a standard for the design, conduct, performance, monitoring, audit, 
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record, analysis, and report of CTs. There are 13 GCP principles presented in the ICH-
GCP Guideline (35), which should never be forgotten while conducting a CT.  
 
2.1.3. Classification Systems 
The knowledge I acquired in classification systems concerns specific tools used in 
oncology CTs: Cancer Staging; Performance Status scales; the “Common Terminology 
Criteria for Adverse Events” code and; Tumour Response Evaluation criteria. 
Although these classification systems are applied by the Investigator, understanding 
the applicable classification systems was very useful to me, when collecting the patient’s 
data. 
2.1.3.1. Cancer Staging 
Understanding cancer staging is important, since this knowledge patient’s may 
estimate a patient’s prognosis and help planning his/her treatment (41). Staging systems 
are still evolving and are particular for some pathologies (41).  
As described by the “National Cancer Institute”, the TNM staging system reflects the 
site of the primary Tumour (T) and its size and/or extent, the spread or not to nearby 
lymph Nodes (N), and the number of tumours and Metastasis (M) (41). The TNM 
designation is applicable to most types of cancer. However, for example, breast and 
prostate cancers have their own grading systems (42).  
In the context of the Pathology Clinics where I developed my traineeship, I also 
acknowledged other classification systems:  
• The “International Federation of Gynaecology and Obstetrics” staging, also 
based on the TNM system, regards cancers of the cervix, uterus, ovary, 
vagina, and vulva (41). This system is applied on the Pathology Clinic of 
Gynaecology.  
• The Gleason score, used to grade prostate cancer in the Pathology Clinic of 
Urology, based on biopsy samples taken from the prostate gland (42). 
• The Children’s Oncology Group staging (41), used in the Pathology Clinic of 
Paediatrics.  
The cancer stage is an important eligibility criterion when screening a patient for a CT. 
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2.1.3.2. Performance Status 
The most used scale for assessing a performance status is the Eastern Cooperative 
Oncology Group (ECOG) performance status. This performance status assessment 
consists of how a disease is progressing, and how the disease affects the patient’s daily 
life activities (43). A lower score reflects the greater ability of the patient to perform daily 
life activities. Another scale is also used in some CTs: the Karnofsky Performance Status. 
A higher score mirrors the patient’s ability to carry out daily life activities (44). The Lansky 
Scale is the Karnofsky scale applied to people under 16 years old (45). Figure 7 presents 
a table with the equivalence between the aforementioned scales. 
The performance status evaluates the patient’s wellbeing, which is an important data 
to be collected, and may also be an eligibility criterion for entering a CT. I acknowledged 
these scales in my daily routine activities. 
 
Figure 7. Conversion Table from ECOG to Karnofsky/Lansky Scales (45) 
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2.1.3.3. Common Terminology Criteria for Adverse Events v 4.0 
The National Cancer Institute “Common Terminology Criteria for Adverse Events” (46) 
is a useful tool widely used in Oncology CTs to report AEs. It consists of a descriptive 
terminology organised by System Organ Class, and associated to grading scale on 
severity for each AE term (46). Each term represents a specific event, used for reporting. 
The last available version, and most used, is v4.0, which grading is represented in Table 2 
(46). However, there are some CTs still using the version 3.0. In those CTs I had to 
consult the v3.0 in order to perform data entry activities accordingly. 
 
Table 2. General guideline for AE severity grade [adapted from (46)] 
Grade Severity 
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
2 Moderate; minimal, local or non-invasive intervention indicated; limiting age-
appropriate instrumental Activities of Daily Living. 
3 Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
self-care Activities of Daily Living. 
4 Life-threatening consequences; urgent intervention indicated. 
5 Death related to AE. 
 
This was a very important tool to acknowledge, since a SC has to report AEs to the 
Sponsor. This data has to be recorded in the patient’s PHR, in order to be reported in the 
CRFs. Nevertheless, understanding this classification system is very useful when 
reporting an AE. Also, a SC may help the Investigator to comprehend this system, as it is 
not mandatory in the normal clinical practice.  
2.1.3.4. Tumour Response Evaluation 
The “Response Evaluation Criteria In Solid Tumours” v1.1 (47) is a set of published 
rules, by an international collaboration, that define the response of cancer patients to 
treatments, through image assessments. These criteria are widely used both in adult and 
paediatric CTs (48). They objectively assess the response of measurable lesions, non-
measurable lesions, target lesions, and non-target lesions (47). Other criteria for 
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evaluating tumour response are those published by the World Health Organisation, by 
evaluation of change from baseline while on treatment. However, these criteria have been 
modified over the time and are often considered confusing (48). While reporting data to 
the Sponsor, it is important to understand these response evaluations, to ensure that the 
reported data is accurate and correct. 
The Prostate Cancer Clinical Trials Working Group 2 has recommendations, for the 
evaluation of bone scans, widely used in Prostate CTs. According to this group, if the 
bone scan indicates progression, and there are not any other exams supporting 
progression, it should be considered progression when at least two or more new lesions 
are observed on bone scan, compared with the baseline scan (49). 
 
2.1.4. Case Report Forms 
To record the CT’s data in the Sponsor’s database, it is required training and skills in 
“Electronic Data Capture” systems, called “Electronic Case Report Forms” (e-CRF). Thus, 
as SC trainee, I performed trainings, to be skilled in systems such as: Medidata Rave® 
(50); InformTM (51); Oracle® (52) and; DatatrackTM (53). The training I received was either 
in online training systems or orally, and lectured by my supervisor. These systems enable 
the record of information on the patient to the Sponsor, according to each investigation 
protocol (54). Thus, these systems are adapted to each CT, and its use ends up being 
intuitive. The e-CRF completion allows the capture, review, management, storage, 
analysis, and report of data, in a systematic basis (54).  
In CTs performed years ago, this data recording systems were not electronic, they 
consisted of proper paper forms provided by the Sponsor. I had the opportunity of 
consulting one of those CRFs. The e-CRFs facilitated the archive and transport of data, 
since these data capture systems can be very extensive and the online systems save a 
huge amount of paper and time.  
Understanding the aforementioned systems is very important, to report the patient’s 
data with accuracy. The activities concerning data reporting will be detailed in sections 
2.2.1.7 and 2.2.1.8. 
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2.1.5. Interactive Response Technology 
Interactive Response Technology provides automated confirmation of assignments, 
both to the centre, in order to proceed with the assignments; and to the Sponsor, 
functioning as a regular reporting of CT activities progress (55).  
This technology can be an Interactive Voice Response System (IVRS) or Interactive 
Web Response System (IWRS). These systems are used by the SC to screen the patient 
(after that, the patient can start the screening procedures); randomise the patient 
(assignment to the study treatment arm); assignment of study visit, to dispense the study 
medication; and to discontinue the patient’s treatment. Screening failures are also 
registered in the IVRS/IWRS system. Furthermore, these systems are used to manage kit 
supply, acknowledge study drug receipt, and register an unscheduled visit. 
IVRS consists of an automated phone call, by steps, and provides automated 
confirmation of assignments via fax. IWRS consists of an intuitive online system, and 
provides the confirmations via e-mail or in the online system itself (55). The IWRS allows 
users to observe the study progress, which is an advantage comparing to the IVRS (55). 
I had the opportunity to acknowledge different IVRS/IWRS technologies, such as 
ClinPhone, ICOPhone, Almac, Bracket, IRT. Understanding this technology is important to 
perform these tasks efficiently. I observed these systems being used several times during 
my traineeship, and they are very intuitive.  
 
2.1.6. Standard Operating Procedures 
In the final stage of the traineeship, I was enrolled in the activity of writing four 
Standard Operating Procedures: Pre-screening; Screening; Randomisation/Treatment 
Initiation; and Study Termination. This activity included the development of flowcharts 
describing these procedures.  
The general objective of the procedures was to harmonize the activities performed in 
each stage of the CT. The procedures define responsibilities and a list of the steps of the 
activities that are assigned to the team member, at IPO-Porto and according to GCP. The 
procedures apply to the elements of the CT team that participate in each stage, primarily 
to the Investigators and SC. The documents have been submitted and revision (and 
subsequent approval) is pending. 
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2.2. SPECIFIC TRAINING 
The study coordination activities developed at UIC will be presented by chronological 
order in which they were performed. This order reflects a growing degree of specificity, 
and responsibility of the tasks within UIC. Every activity I performed was supervised, and 
corrected or improved when needed. At first, I started assisting the Pathology Clinics of 
Digestive and Lung. After that, I started assisting the clinics of Lung, Gynaecology, 
Urology and Paediatrics. 
 
2.2.1. Initial Training Activities 
At the beginning of my traineeship, I did mainly organisational activities, which allowed 
me to understand the role, importance and the articulation of each document at UIC, and 
where I could find them. I understood that, when conducting a CT, “what is not written, did 
not happen”. Thus, it is crucial to keep records and maintain them up-to-date.  
After these activities, I accumulated other tasks, related with the files aforementioned 
in the dossiers’ description, such as processing the patients’ expenses, preparation of 
study visits, and schedule of exams and visits.  I then started participating in other type of 
activities, such as data reporting, assistance to monitoring visits and site initiation visits. 
These activities are transversal to all CTs. 
2.2.1.1. Dossiers 
The dossiers that are part of a SC daily routine and with which I worked were: 
• The Investigator’s Site File  
This dossier is provided by the Sponsor and contains all the information on a CT, 
namely the Investigation Protocol and further amendments (when applicable), the 
Investigator’s Brochure, ICFs (updated and obsolete versions), Laboratory Manual, CRF 
Completion Guidelines, Delegation Logs, Curricula of the CT staff, Training certificates, 
correspondence, and all information that may apply. 
I archived documents in the File, in the proper section. Also, I identified if there was 
any section with missing information and documents, so that they could be requested and 
properly archived to complete the dossier. This activity allowed me to understand what 
type of documentation a SC has to gather after a CT’s approval and the timelines for 
those activities. This also helped me to understand the importance of updating the 
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documents, such as new versions of the Protocol or of the ICF. For example, when there 
is a new ICF, it has to be archived in the Investigator’s Site File, and a copy of the 
obsolete versions must remain there, properly identified with the word “obsolete”, so that 
the old versions are not used. Regarding this particular case, every superseded document 
has to be replaced in other dossiers, such as the workbook, so that no old versions are 
used. 
• The Workbook 
This dossier consists in a compilation of the everyday material of a CT (in blank), 
being used for the patients’ visits. It may be provided by some Sponsors, or may be 
organised from scratch by the SC. Although not mandatory, this dossier is very helpful 
and practical when scheduling and preparing the patients’ visits. The type of materials 
found in a workbook are usually: ICFs, Eligibility Criteria worksheets, Screening and 
Randomisation worksheets (if required), Prescription sheets (IPO document), Exams 
requisitions (usually provided by the Sponsor), IP administration worksheets (for 
intravenous administration) or the medication diary (for oral medication), AE diaries (if 
applicable), and any other document that may apply to a given CT and that is mandatory 
to be filled in the patients’ visits. These materials should always be updated if there is any 
further version or amendment of the same. 
I completed workbooks, starting with the organisation of the study materials of two 
CTs from the Digestive Clinic. As these CTs had several study materials, I added an index 
to each workbook, to facilitate its navigation. This activity allowed me to familiarise with 
the type of study documents that are part of the routine of patients’ visits and to 
understand the SC’s role in ensuring that every necessary material is available for 
completion during the patients’ visits. 
• The Patient’s File 
This dossier may be provided by the Sponsor in some CTs. However, UIC has its own 
organisation, regarding this dossier. This dossier contains the patient’s data, regarding 
his/her participation in the CT. The following data can be found in this dossier: ICF 
(original, if not required to be archived in the ISF by the Sponsor), Screening and 
randomisation confirmations, exams’ requisitions and respective confirmations, copy of 
IMP prescriptions and confirmation of medication dispensing (when applicable), local 
laboratory analysis reports, clinical diary (recorded by the investigator in each study visit) 
and follow-ups, End of Treatment confirmation, SAE reports if applicable, other 
information specific of each CT such as questionnaires and medication or AE diaries. 
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Besides organising this dossier for new patients, I also archived data on existing 
dossiers and identified the need for updating data or ask for validation (investigator’s 
signature). This activity allowed me to understand the main data to gather and keep up to 
date concerning the patient’s participation in the CT, as well as the data that should be 
available for the monitoring visits and CRF completion.  
• The Patient’s Personal Health Record 
The PHR gathers the patient’s data at IPO-Porto since his/her registration at the 
institution (excluding data that is electronic). When in a CT, the patient’s PHR is identified 
as belonging to UIC. This means that when not in use in other departments of IPO-Porto, 
the PHR should be archived in UIC’s facilities. Also, a label is added to the PHR, so that 
other departments easily acknowledge that the patient is participating in a CT. the 
following data concerning the CT is present in the PHR: ICF (copy), record sheets from 
UIC, prescription sheets, IMP administration worksheets or other nursing records, dipstick 
analysis report, Imaging reports (such as Computed Tomography or Bone scan), and 
central laboratory analysis reports.  
This is the file that serves as contact between UIC and the Pathology Clinics, or the 
Day Care Hospital and central of analyses, and that circulates within IPO-Porto facilities. 
My role was archiving and verifying the data. I realised the importance of the filling of 
those materials and the SC’s role in ensuring that every necessary material is complete 
and accurate. 
2.2.1.2. Processing the patients’ expenses 
Complying with the legislation, the patients participating in a CT have the right to be 
reimbursed for his/her participation in the CT, in regard of the expenses of the patient’s 
traveling for the study visits and meals (or eventually AE management medication). For 
this matter, UIC has a form where the expenses are described, for further verification by 
the financial assistant and analysis by the Sponsor, whom reimburses the patient.  
The patient delivers his/her expenses to the investigator, who forwards it to UIC. As a 
SC trainee, I received the patients’ expenses and matched the date of the receipts with 
the study visits the patient performed, detailing this data in the form. This procedure 
justifies the patient’s expenses, ensuring they are related with the CT. If there are any 
receipts that do not match any study visit in any way, those receipts are forwarded to the 
patient. After completing the form I anonymised the receipts related with study visits, and 
forwarded them, with a copy and the form verified and signed by the SC, to the financial 
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assistant. This is an important procedure, since data that could identify the patient cannot 
be sent to the Sponsor.  
2.2.1.3. Preparation of study visits 
The PHR is the contact point between UIC and other departments. When a patient has 
a scheduled study visit, the SC prepares the patient’s PHR with the data that needs to be 
collected by the Investigator and nurses. My role was to compile all the documents that 
needed to be filled on that given visit according to the protocol, which are present in the 
workbook (these forms are aforementioned in section 2.2.1.1, regarding the workbook). 
Thus, I gathered the blank forms of that given CT and filled the patient’s number and other 
applicable data (for example: name, date of birth, number of visit, date). I also composed 
a UIC’s record sheet, listing the procedures that needed to be performed on that visit per 
protocol, and what should be scheduled for the following visit.  
2.2.1.4. Agenda of UIC 
For UIC’s internal organisation of activities, a calendar is made every month, recording 
the patients’ visits. Each coordinator records the activities referring to the respective 
Pathology Clinics. The calendar is also sent to the Study Nurse responsible for taking 
patients’ biological samples, detailing the patient’s study visit number. I had the 
opportunity to complete the calendar, recording the activities of the Pathology Clinics of 
Digestive and Lung, in given months. This improved my organisational skills and made me 
realise the workload of a SC and some of the aspects that are part of a SC’s daily routine. 
Another agenda that is kept is the monitoring visits schedule. This is important for the 
management of UIC’s facilities, since it has to be ensured that the offices are ready for the 
monitoring visits, with the necessary materials available for the visit. The SC schedules 
the visits and the operational assistant prepares the monitoring offices. 
2.2.1.5. Schedule of patient’s exams 
Regarding the schedule of patient’s exams, it is very important to comply with the 
protocol requirements, so that there are no protocol deviations. Also, the cooperation of 
the laboratories is crucial, ensuring the results are available on time. Regarding the study 
visits scheduling, some of the Pathology Clinics implemented a system of reserving a 
number of vacancies specific for CTs. This ensures compliance with protocol. As a SC 
trainee, I scheduled imaging exams. For that, I sent the exam requisition signed by the 
Investigator to the imaging laboratory, by fax. Then, I received the confirmation with the 
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scheduled event, complying with the time window I requested. If needed, I would 
telephone the contact person in the laboratory to schedule the exam. Then, I would 
contact the patient and let him/her know the date of the exam.  
While performing the activities mentioned in the last sections, it is essential to have 
attention to detail, so that no mistakes are done. I understood the functioning and 
organisation of UIC, and what is needed to perform a SC’s tasks rigorously and on time, 
always complying with the protocol and GCP. 
2.2.1.6. Training challenge 
With the evolution of UIC, the scheduling and archiving tasks were assigned to the 
CTA. However, these are very important tasks to be familiarised with, since they show the 
organisation and functioning of UIC. 
During my traineeship, two CTAs joined the UIC’s team. I had the opportunity to 
accompany one of them for a brief period of time, helping her to familiarise with UIC’s 
procedures. This was a challenging opportunity that tested my knowledge and 
communication skills, since I had to convey the learning I had received until then. 
2.2.1.7. Completion of e-CRFs and queries resolution 
E-CRF completion activities allow the Sponsor to access the patients’ data, regarding 
the CT. The data usually reported in the e-CRF concerns medical history, demographics, 
diagnosis, study medication dispensing, date of study visit, laboratory results, imaging 
results, AEs, concomitant medication, questionnaires and other data that may apply.  
Data is available in the PHR and should by reported within the timelines defined in the 
protocol (usually within 5 days after the study visit). Before entering the data in the e-CRF, 
I verified if it was complete, so that amendments could be done if necessary. 
Understanding the classification systems mentioned in the generic training section was 
very useful when filling e-CRFs. I had the opportunity of performing data entry and query 
resolution in e-CRFs of the Pathology Clinics of Digestive, Lung, Gynaecology, 
Paediatrics and Urology. E-CRF completion ends up being an intuitive task.  
After data entry, queries may be generated (automatically, or by CRA, Data Manager 
or Medical Manager). Usually, queries have a response period of 5 working days. If they 
are automatically generated, they should be addressed immediately. It is important to 
answer in time, in order to clarify any doubts regarding the data.  
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Regarding the e-CRF completion activities, I also had the opportunity to prepare an 
interim analysis and database lock. The preparation of interim analysis and database 
locks imply that all the subjects’ data is recorded in the e-CRF, and all queries are 
answered, according to the established timelines.  
The e-CRF activities allowed me to test my time management skills and aptitude of 
complying with deadlines. The activities I performed were supervised. 
2.2.1.8. Serious Adverse Events Reporting 
SAE reporting was another important activity regarding the data to be reported. A SAE 
must be immediately reported to the Sponsor (35), and as defined by the protocol 
timelines: usually 24 to 48h after its acknowledgement. This procedure may require a form 
filled by the Investigator, reporting the SAE, and sent to the Sponsor, or may be reported 
by the SC in the e-CRF. If the SAE is reported in a paper form, queries may be received 
and answered afterwards by the same system (usually fax). I have reported SAEs in e-
CRFs, and answered to queries related to them. This activity was supervised, and done in 
the Pathology Clinics of Lung and Paediatrics. 
2.2.1.9. Site Initiation Visits 
I had the opportunity to participate in 8 Site Initiation Visits, so that I would have an 
overview of different phases and Pathology Clinics of CTs conducted in IPO-Porto. These 
data are resumed in Table 3.   
 
Table 3. Participation in Site Initiation Visits, per Pathology Clinic and type of study 
[adapted from (56)] 
Pathology Clinics Number of Initiation Visits Type of study 
Breast 1 Phase II 
Digestive 2 Phase II; Medical Device 
Intensive Care Service 1 Phase III 
Lung 2 Phase II/III; Phase III 
Onco-Haematology 1 Phase III 
Soft Tissue and Skin 1 Phase I 
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These visits are usually specific for the Investigators and SC, study nurses, and 
pharmacists. The CRA conducts the initiation visits, for each team, on the scheduled 
dates. The following aspects are presented in site initiation visits for Investigators: a) 
Study objectives; b) Endpoints; c) Eligibility Criteria; d) Study Design and plan; e) 
Screening procedures; f) Randomisation procedures; g) Study procedures; h) Safety 
activities; i) End of Treatment; j) Follow-up activities and End of Study; k) Study 
withdrawal; l) AEs and SAEs Management and report; m) Investigator Responsibilities. 
At the end of the presentation, the investigators clarified their doubts, and signed the 
delegation log. Then, the CRA provided the study materials to the SC: Patients’ Files with 
ICFs, patient cards, AE diaries and record worksheets. Furthermore, documents were 
organised and archived in the Investigator’s Site File. Additionally, the SC’s usernames 
and passwords for the IVRS/IWRS and e-CRF were provided. 
The CRA also schedules a meeting for the study nurses, regarding CT procedures, 
such as sample collection and IMP administration procedures, as well as issues related 
with the record of data. I participated in one study nurse initiation visit. This visit was 
focussed in the IMP administration and samples’ collection and processing. Also, the 
material for that purpose was installed, and the central laboratory kits, manuals and 
shipping materials were provided.  
During my traineeship, the chief-Nurse of Day Care Hospital, where the intravenous 
IMP is administrated, identified the need to implement a checklist for these visits. This 
checklist would be delivered to the CRA, before the initiation visit, as a suggestion of 
issues to focus in the visit at the Day Care Hospital. Thus, the CRA could be well 
prepared for the needs of the Day Care Hospital, and could know in advance the number 
of nurses present, the schedule for the visit, as well as the place where it is conducted 
(these aspects are standard for all visits). The issues that should be addressed are: 
• Study design; 
• Eligibility criteria; 
• Administration procedures (IMP and/or other medicines); 
• AEs related to the IMP that are predicted to occur, and its management 
(prophylaxis and treatment); 
• Hypersensitivity/allergic reactions that may occur and its treatment; 
• Record sheets ; 
• Written information regarding the CT. 
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This checklist will be sent to the CRAs, whenever a new CT initiates at IPO-Porto, to 
improve its efficiency. Another initiation visit is conducted in the Pharmaceutical Services, 
regarding the preparation of medication and supplies, as well as specific documentation. 
These presentations serve as training, and the CT team has to be properly trained before 
starting the CT activities.  
 
2.2.2. Pathology Clinics Specialisation  
As my traineeship evolved, I got enrolled to the study coordination activities of the 
Intensive Care Service and the Pathology Clinics of Lung, Gynaecology, Urology, and 
Paediatrics. The CTs in which I participate were all sponsored by the industry, and all 
Prospective, Multi-Centric and Multi-National (except MuTAR, which is National). In this 
context, I briefly describe the CTs in which I was involved, in the Pathology Clinic of 
Urology (Table 4), in the Pathology Clinic of Lung (Table 5), and in the Pathology Clinics 
of Gynaecology, Paediatrics, and the Intensive Care Service (Table 6). 
 
Table 4. Urology Clinical Trials [adapted from (56, 57)] 
CT Acronym 
(EudraCT Number) 
Purpose Study 
Design 
C21004 
(2010-018661-35) 
To compare Orteronel plus Prednisone vs Placebo plus Prednisone in 
patients with chemotherapy-naive metastatic castration-resistant prostate 
cancer 
Randomised, 
Double-Blind 
C21005 
(2010-018662-23) 
To Compare Orteronel plus Prednisone vs Placebo plus Prednisone in 
patients with metastatic castration-resistant prostate cancer that has 
progressed during or following Docetaxel-based therapy 
Randomised, 
Double-Blind 
FIRSTANA  
(2010-022064-12) 
To compare two doses of Cabazitaxel in combination with Prednisone vs 
Docetaxel in combination with Prednisone, in patients with metastatic 
castration-resistant prostate cancer not pre-treated with chemotherapy 
Randomised, 
Open-Label 
LATITUDE  
(2012-002940-26) 
To compare Abiraterone Acetate plus low-dose Prednisone plus Androgen 
Deprivation Therapy (ADT) vs ADT alone in subjects with high-risk 
metastatic prostate cancer not pre-treated with hormonotherapy 
Randomised, 
Double-Blind 
METEOR 
(2013-001010-14) 
To compare Cabozantinib vs Everolimus in subjects with metastatic renal 
cell carcinoma that has progressed after prior VEGFR tyrosine kinase 
inhibitor therapy 
Randomised, 
Open-Label 
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Regarding the CTs conducted in the Pathology Clinic of Urology (Table 4), most of 
them were for prostate cancer. Only one was for renal carcinoma, which was a novelty, 
since there were not any CTs for the kidney at IPO-Porto. Regarding the CTs C21004 and 
C21005, I only had the opportunity to participate in a small number of activities, since the 
patients’ visits were not very regular. Regarding FIRSTANA, I participated in many tasks, 
although the number of patients included in the CT was bigger for patients in follow-up. I 
participated in several monitoring visits and had the opportunity to prepare the e-CRF for 
an interim analysis. LATITUDE was the CT of this clinic in which I performed more variety 
of activities, and contributed the most. METEOR started during my traineeship. Thus, I 
had the opportunity to accompany the initiation of a CT in this clinic.  
 
Table 5. Lung Clinical Trials [adapted from (56, 57)] 
CT Acronym 
(EudraCT Number) 
Purpose Study 
Design 
1200.55 
(2009-017661-34) 
To assess afatinib in 1st line or chemotherapy pre-treated patients with 
locally advanced or metastatic non-small cell lung cancer harbouring 
EGFR mutation(s) 
Open-Label 
Ideate 
(2009-017396-19) 
To compare the efficacy of Ipilimumab plus to Paclitaxel and Carboplatin 
vs Placebo plus Paclitaxel and Carboplatin in subjects with stage 
IV/recurrent non-small cell lung cancer 
Randomised, 
Double-Blind 
LUX-Lung 8 
(2011-002380-24) 
To compare afatinib vs Erlotinib in patients with advanced squamous cell 
carcinoma of the lung as second-line therapy following first-line platinum-
based chemotherapy 
Randomised, 
Open-Label 
MK-3475-010 
(2012-004391-19) 
To compare two doses of MK-3475 (SCH900475) vs Docetaxel in 
previously treated subjects with non-small cell lung cancer 
Randomised, 
Open-Label 
MuTAR 
(2010-022509-17) 
To assess Erlotinib (Tarceva®) treatment in patients with locally advanced 
or metastatic non-small cell lung cancer who present activating mutations 
in the tyrosine kinase domain of the epidermal growth factor receptor. 
Open-label 
 
Concerning the Pathology Clinic of the Lung (Table 5), I accompanied CTs that were 
in its last phase within the study coordination context (LUX-Lung 8), CTs that were active 
when I started the traineeship (Ideate and MuTAR), and new CTs, that I accompanied 
since the site initiation visit (1200.55 and MK-3475-010). The new CTs and Ideate were 
the CTs in which I most contributed.  
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Regarding the Pathology Clinic of Gynaecology (Table 6), I verified that the staff was 
familiarised with the procedures. This aspect mirrors the CTs situation: the CTs are 
conducted at IPO-Porto since years ago, and the treatment period is long. 
 
Table 6. Other Pathology Clinical Trials [adapted from (56, 57)] 
CT Acronym 
(EudraCT Number) 
Purpose Study 
Design 
Gynaecology    
ROSiA 
(2010-019525-34) 
To assess the addition of Bevacizumab to Carboplatin and Paclitaxel as 
front-line treatment of epithelial ovarian cancer, fallopian tube carcinoma or 
primary peritoneal carcinoma 
Open-Label 
TRINOVA-1 
(2010-019821-32) 
To compare Paclitaxel plus AMG 386 vs Paclitaxel plus Placebo in women 
with recurrent partially platinum sensitive or resistant epithelial ovarian, 
primary peritoneal or fallopian tube cancers 
Randomised, 
Double-Blind 
Intensive Care 
Service 
  
INHALE 2 
(2008-000906-35) 
To evaluate the safety and efficacy of BAY 41-6551 as adjunctive therapy 
in intubated and mechanically-ventilated patients with gram-negative 
pneumonia 
Randomised, 
Double-Blind 
Paediatrics   
MK-0517-029 
(2012-002340-24) 
To evaluate the pharmacokinetics/pharmacodynamics, safety, and 
tolerability of Fosaprepitant in pediatric patients for the prevention of 
chemotherapy-induced nausea and vomiting (CINV) associated with 
emetogenic chemotherapy 
Randomised, 
Partially-
Blinded 
Unspecified   
MK-0517-031 
(2012-001718-41) 
To examine the efficacy and safety of intravenous Fosaprepitant 
Dimeglumine for the prevention of chemotherapy-induced nausea and 
vomiting associated with moderately emetogenic chemotherapy 
Randomised, 
Double-Blind 
 
Regarding the Pathology Clinic of Paediatrics (Table 6), I verified that the 
Investigational Team was still getting used to CTs, and is still evolving. The same was 
verified in the Intensive Care Service (Table 6). These clinic and service have a few 
specificities related to the patient populations that will be further discussed in this report. 
For this reason, the Investigational Teams also needed more support. 
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In addition to the activities I already had performed in these clinics, I started 
participating in monitoring visits and assisting to patients’ clinic visits when possible. I also 
had the opportunity of sending biological samples for the patient’s screening. These 
activities allowed me to understand the patient’s circuit within IPO-Porto, and some of the 
oncology specificities.  
During my traineeship, I did many tasks, whenever they would surface (as previously 
mentioned). For this reason, those activities were not developed according to a normal 
CTs’ conduction order, but according to the situation when they would be needed. Figure 
8 presents a flowchart describing the order of the CTs’ tasks conduction in each patient 
visit at IPO-Porto, if we would consider a single CT from its initiation at the site until its 
termination, from the SC’s perspective. The activities I performed in each CT are 
described in Table 7. 
 
Figure 8. Study Coordination activities sequence per stage of CT 
  
 
 
Documents management and verification 
Update of UIC’s database 
Collection and record of data in the PHR 
     CRF completion 
            Preparation of study visits and patients’ expenses 
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Table 7. Study Coordination Activities performed in different Clinical Trials  
 Study visits1  Other activities 
ICF Screening Randomisation Treatment End of Treatment Follow-up  e-CRF Monitoring visits Documents management 
Sample 
shipment 
Urology            
C21004    x      x  
C21005    x      x  
FIRSTANA     x x x  x x x  
LATITUDE  x x x x x   x x x  
METEOR x x x       x  
Lung            
1200.55 x x x x    x  x  
Ideate x x x x x x  x x x  
LUX-Lung 8      x  x x x  
MK-3475-010 x x x x      x x 
MuTAR    x  x  x x x  
Gynaecology             
ROSiA    x x x  x  x  
TRINOVA-1    x    x x x  
Intensive Care             
INHALE 2          x  
Paediatrics            
MK-0517-029   x x x x  x x x  
Unspecified            
MK-0517-031 x x x x x x  x  x  
                                                          
1 Study visits imply preparation of the visit, and scheduling of exams 
Activity 
CT 
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As described in Figure 8 and Table 7, Study visits’ preparation was an activity I 
performed systematically. The treatment preparation occurred more often, since this visit 
is more frequent (for example, screening and randomisation occur only one time). 
Regarding other activities, I performed documents management and e-CRF completion on 
a daily basis. Documents management was an activity transversal to all CTs, and to all 
stages of CTs’ conduction, which I performed systematically. I also had the opportunity to 
assist monitoring visits of several studies, and to perform sample shipment of one CT. 
2.2.2.1. Monitoring visits 
Regarding monitoring visits, it is important to clarify that this is the moment when the 
Sponsor (in this case, the CRA delegated for the study) has access to the source 
documents. In these visits, the CRA’s main role is to verify that the rights and well-being of 
the subjects are protected, that the reported data is complete and consistent with the 
source documents, without discrepancies, that there is compliance with the protocol, 
regulatory requirements and CGP, and identify action items for follow-up (35). The 
responsibilities of the CRA are described in (35). I had the opportunity to participate in 
monitoring visits. The SC’s main role is to clarify the CRA, regarding the reported data, 
and to meet the action items identified in the monitoring visit. When necessary, the 
Investigator(s) should also be present. 
Before the scheduled visit, I would prepare and organise all dossiers (Patient’s File, 
PHRs, Investigator’s Site File), to check if there was the need of archiving new documents 
or ask for updates of missing or inconsistent data. If so, I would note the aspects that 
needed the Investigator’s amendment or clarification, so that the data could be updated in 
the monitoring visit. Also, I would verify if the e-CRF was up-to-date and proceed to its 
completion, and answer to queries when necessary. When I had any doubt related with 
the e-CRF completion, I would clarify with the CRA during the visit. I consider that the 
monitoring visits are a common effort to ensure that all documentation is accurate, and to 
meet the protocol requirements and data reporting issues.  
2.2.2.2. Patient’s visits 
During my traineeship, I had the opportunity to be present in study visits required per 
protocol, in the Pathology Clinics of Urology and Lung and in the CT MK0517-031 
(conducted in several clinics). 
In these visits, the Investigator evaluates the patient’s physical and clinical condition, 
and records the data, usually ECOG, physical exam, concomitant medication, evaluation 
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of laboratory results and signs and symptoms according to the “Common Terminology 
Criteria for Adverse Events” code, and RECIST evaluation when imaging is available. 
There are other requirements of data to be recorded and reported, that vary according to 
the type of study visit: Screening, Randomisation, Treatment, End of Treatment, and 
Follow-up.  
UIC has a database with the list of potential patients and patients included in each CT. 
When the Investigator signals the patient, I update this database with the patient’s data. 
When the patient enters the screening, randomisation, treatment phase, follow-up, or end 
of study, I update the patient’s status in the database. 
The next sections expose the study coordination activities to be performed when 
assisting to visits, but also the activities performed before and after the visits, and 
therefore likewise respective to the Pathology Clinics of Gynaecology and Paediatrics.  
2.2.2.3. Pre-screening (Informed Consent Form) 
When an Investigator signals a potential patient for a CT, he/she contacts the SC, so 
that she can be prepared to provide an ICF to the Investigator on the scheduled date, as 
well as the checklist of Inclusion/Exclusion Criteria.  
In the pre-screening visit, the Investigator explains the CT to the patient and study 
procedures, and clarifies the patient’s doubts, emphasising that the patient may withdraw 
consent at any time. Training in GCP is very important while the ICF is being explained, 
so that the Investigator does not influence the patient’s decision. The patient should take 
the ICF home and make a thoughtful decision. Another visit is scheduled for any 
clarifications, and eventual inclusion in the CT. After signing the ICF(s), if the study 
protocol allows and the patient agrees, the screening visit can be performed in this same 
visit.  
As a SC trainee, I ensured the data was appropriately recorded in the PHR, since it is 
required that the delivery of an ICF is recorded, and assisted the SC in the schedule of the 
patient’s screening exams. The data to be recorded is the identification of the current 
version of the ICF(s) and date, and whether the patient signed or not the ICF(s)—or the 
date when the patient has an appointment to provide his/her decision. I also verified if all 
ICF fields were filled by the patient and the Investigator, and provided a copy to the 
patient. After that, the SC would inform the patient about the expenses reimbursement 
and the screening exams foreseen schedule.  
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In some CTs, there are two separate ICFs (or even more) for the patient to sign. The 
general ICF is mandatory for the patient to sign, in order to participate in the CT. There 
are also other types of ICF, which are optional: Pharmacogenetics and/or 
pharmacogenomics ICF; Biological samples repository ICF; Future Biomedical Research 
ICF. If the patient wants to participate in the optional study, he/she has to perform 
additional biological tests or provide his/her data. Regarding the Future Biomedical 
Research, I had the opportunity to perform an online training on the matter and receive a 
certificate. This was important in order to know how to track these ICFs and record the 
patients’ participation in the e-CRF, as well as being aware of what are the procedures to 
be done if a patient withdraws the consent anytime during or after the study. 
2.2.2.4. Screening  
Right after the patient gives his/her consent, the SC registers the patient in the 
IVRS/IWRS system, and obtains the patient’s screening number, which identifies the 
patient in the study. A screening confirmation is obtained by fax, e-mail, or in the IWRS 
system. I have assisted to these steps, and learned how I should proceed. For example, 
some IWRS systems ask a small number of questions in order to screen the patient. 
These questions may be related to the eligibility criteria of the CT, and the SC may not be 
aware of the answer. Thus, the SC contacts the Investigator, in order to obtain an answer 
and proceed with the screening. This information should be recorded in the patient’s PHR.  
After obtaining the screening confirmation, the exams can be scheduled. The 
Investigator also has to record the physical and clinical evaluations, and record other 
required data, such as demographics, medical history and diagnosis, as well as the 
aforementioned data usually recorded in all study visits. I consulted the protocol, to ensure 
all exams were scheduled within the window timeline required by protocol, and its results 
available on time. Then, the patient would be informed of the screening schedule.  
• Sample shipment 
In protocols requiring tumour samples shipment to a central laboratory, I wrote a letter 
to the Pathological Anatomy Service of IPO-Porto, requesting the solid tumour sample of 
the patient. Together with the letter with the patient’s information, I sent a previous 
histological report that might be available, for their orientation, and the shipping form if 
there was any information I could not gather myself.  
After that, I received the sample and the complete form, and packaged the kit 
according to the shipping manual instructions of that specific protocol. Then, the SC 
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contacted the courier for scheduling the sample collection, and registered the reference 
number. Until this step, I acquired knowledge about the procedures concerning sample 
shipping at UIC. Then, I gathered the copy of the form and sent it by e-mail to the required 
address, with the expected information. I then archived the documents used in this activity 
in the Patient’s File. The blood samples shipment is done by the study nurse.  
2.2.2.5. Randomisation/Treatment initiation  
After the screening visit, and before the patient’s randomisation/treatment initiation, 
the Investigator evaluates the eligibility criteria: inclusion criteria and exclusion criteria. For 
this, the Investigator evaluates the results of the patient’s screening exams. There are 
other factors to consider. For example, the patient’s inability to fill in a diary may be an 
exclusion criterion, as it can mean non-compliance to the protocol. The Investigator 
performs the usual physical and clinical evaluation and records the required data per 
protocol in the PHR. The Investigator then fills the eligibility criteria form. If the patient 
does not meet the criteria, it is considered a Screening Failure, and registered in the 
IVRS/IWRS system as a screening failure by the SC. If the patient meets the criteria, 
he/she is randomised in the IVRS/IWRS system by the SC, and the patient stays allocated 
to a treatment arm. The medication is assigned to the patient in the same system.  
In some CTs, the Sponsor may require a Qualification Visit before the randomisation 
visit, to assess a number of eligibility criteria, and other issues that may apply. The step 
that follows randomisation is the dispensing of study medication, which is described in the 
following section. The randomisation is done in the CTs with that design. When the study 
design does not require randomisation, this step is not done, and this visit is considered 
the study treatment iniation. 
2.2.2.6. Treatment  
The patient has study visits according to the schedule defined in the protocol, to 
evaluate his/her status and receive or discontinue the treatment. I prepare these visits 
according to the description provided in section 2.2.1.3. During the visit, the Investigator 
contacts the SC to assign the study treatment. The visit is registered in the IVRS/IWRS 
system, and the medication is dispensed. When applicable, the treatment batch number 
will be delivered. After that, the SC contacts the Investigator, to transmit the batch/box 
number.  
The Investigator prescribes the medication using the prescription sheet specific for the 
CT, which was sent in the preparation of the study visit. Then, the operational assistant 
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brings a copy of the prescription to UIC. I write a letter, stating that the patient has been 
assigned the medication, and send it to the pharmacy by fax, with the prescription copy 
and the IVRS/IWRS confirmation attached. These documents and the fax confirmation are 
then archived in the Patient’s File. If the patient is discontinuing the treatment, that 
information is registered in the PHR, and the medication is not assigned. Instead, an End 
of Treatment visit is scheduled according to the protocol window. 
When the medication is oral, the Operational Assistant gathers the assigned 
medication from the Pharmacy, delivers it to the patient, and receives the medication left 
from the previous treatment cycle (and the medication diary, if applicable). This procedure 
is registered by the CTA. The patient takes home a medication diary, if required per 
protocol, and returns it filled in, in the next scheduled visit.  
When the study medication is intravenous, it is administered in Day Care Hospital, by 
the study nurse, whom registers the procedure in the CT worksheets sent in the 
preparation of the PHR. 
After the study visits, I archive the documents and fill the CRFs, with the supervision of 
the SC, as explained in section 2.2.1.7.  
As my traineeship evolved, I understood the patient’s treatment circuit within IPO-
Porto during his/her visit: 
First of all, the patient goes to the Pathology Clinic, and has a Nurse appointment, 
where the Study Nurse measures the patient’s vital signs, and delivers the CT 
questionnaires if applicable (in some Pathology Clinics, this step may not occur, or be 
performed immediately before the Investigator’s evaluation). Then, the patient goes to the 
central of analysis at IPO-Porto, where the Study Nurse performs the study procedures 
regarding biological sampling, for the local laboratory and/or the central laboratory (when 
and if applicable). If there are any other procedures to be performed at IPO-Porto before 
the Investigator’s evaluation, the patient proceeds to the next service (for example 
cardiology service to perform an ECG, or nuclear medicine to perform a bone scan). After 
that, the patient has his/her appointment with the Investigator, at the Pathology Clinic. 
This is when the Investigator evaluates the results of the blood tests and other exams, to 
assess the patient’s condition.  
If the patient proceeds the treatment cycle, he/she receives the medication, after it has 
been assigned by the SC and dispensed by the Pharmacy: if it is oral medication, the 
patient receives the kit from the UIC’s operational assistant; if the medication is 
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intravenous, the patient goes to the Day Care Hospital, and is administered the 
medication by the study nurse. The visit is then complete. If the patient does not meet the 
criteria to continue the treatment per protocol or by investigator decision, another visit is 
scheduled, for new assessment of the patient’s condition, and a medical intervention may 
be performed if necessary. The circuit of a patient enrolled in CTs at IPO-Porto is 
represented in Figure 9 (it should be noted that the study nurse appointment may occur 
only after the study procedures, before the Investigator appointment). 
 
Figure 9. CT Patient’s treatment circuit within IPO-Porto 
 
2.2.2.7. End of treatment 
When a patient ends or discontinues the treatment, he/she has a study visit where the 
Investigator records the data required per protocol and evaluates the patient’s status and 
next course of treatment if applicable. The patient is discontinued in the IVRS/IWRS 
system by the SC, and the reason is provided. The IVRS/IWRS confirmation is archived in 
the Patient’s File. The reasons for ending the treatment may be completion of treatment, 
progression of disease, unacceptable toxicity, AE, non-compliance to protocol, 
Investigator decision, pregnancy or withdrawal of consent. Regarding my experience, I 
verified the end of treatment due to progression of disease (for example in lung cancer), 
completion of treatment (for example in ovarian cancer) and decision of the patient to end 
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the treatment due to its long duration, and with the support of the Investigator (for example 
in prostate cancer).  
When the patient ends the treatment he/she enters the follow-up phase, to be followed 
for toxicity, progression, or survival.  
The data of all CT visits is recorded in the e-CRF. 
 
In the scope of my traineeship, these were the activities in which I was engaged most 
of the time, with emphasis on the Pathology Clinics of Lung, Urology, Gynaecology, and 
Paediatrics. 

 Study Coordination Experience | 51 
 
3. Discussion  
 
3.1. STUDY COORDINATION EXPERIENCE 
Working in a clinical research site with a team with 8 years of experience was a 
challenging opportunity. Every professional had well defined roles and tasks within IPO-
Porto. However, my traineeship, overlapped with the entry of CTAs to the team. Thus, I 
accompanied the evolution and redefinition of tasks that they would be responsible for. 
This was a challenge because, as a trainee, I needed to learn the functioning of the 
institution and familiarise with some processes that were being performed by the CTAs. 
My strategy was to perform myself those tasks, or to understand how the tasks I could not 
do often are done. An example is the telephonic contact with the patients, and with the 
services/laboratories responsible for scheduling exams. I performed those tasks 
effortlessly, but not in a constant basis, what could have been beneficial for understanding 
the communications flow within IPO-Porto. However, I do not consider this a limitation for 
my professional activity, since it is a simple task. 
Regarding my role within UIC, I feel part of the team, and have a close relation to 
them. The biggest challenge occurred during the period of time in which I did not have an 
assigned supervisor (officially). At first, I was not sure whether I could perform some 
activities, and who would be responsible for assigning those tasks. However, I would 
always clarify any doubt that I had, and perform every task that I was given an 
opportunity. As I got confident with my role within UIC, I would ask for a chance to fulfil 
any training gaps, and there was an effort to respond to all of them, which I am grateful 
for.  
Concerning the training and the tasks I performed at UIC, I identified some issues that 
I would like to address. For example, regarding the patient’s clinical data, the documents 
are recorded in an electronic database at IPO-Porto. Thus, in order to keep the Patient’s 
File complete, I had to print the patient’s electronic data, such as laboratory reports and 
the patient’s diary. Therefore, data would be available for monitoring visits and CRF 
completion. There have been some concerns appointed by the Sponsors regarding the 
validity of the electronic PHR. The CRAs do not have access to this system within IPO-
Porto, since it is not possible to restrict their access for each CT. UIC’s strategy was to 
print the clinical diary and ask for the Investigator to sign the patient diary and exams, 
validating the data. This is not easy to implement, since Investigators attend many 
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patients per day, and have to be quick between appointments, what may pose a difficulty 
to print the diary and sign it right away. 
Considering the clinical research area, where there is the component of uncertainty, 
the patient should always be in first place. For this matter, at UIC, SCs always try to help 
in any way they can. For example, reimbursement should be done as quickly as possible, 
since patients that have financial difficulties should not feel obligated to refuse or withdraw 
consent due to this reason. To address this issue, a new procedure is being thought-out 
(12): IPO-Porto reimburses the patient, and then the Sponsor reimburses IPO-Porto. This 
reduces the time the patient dispends while waiting for reimbursement. Therefore, the 
patient can participate in the CT even if he/she has financial difficulties.  
On the topic of the subject’s treatment, there were three different types in the studies I 
was enrolled in: oral treatment; intravenous treatment on Day Care Hospital; and 
intravenous treatment with hospitalization. Considering the SC’s perspective, oral 
medication is the easiest treatment to report in the e-CRFs and the treatment that is more 
comfortable for the patient. However, intravenous medication requires more study 
procedures for the administration of the drug, and sometimes patients may develop 
hypersensitivity reactions. Thus, CTs that involve intravenous treatment, are usually more 
challenging to conduct and less comfortable for the patient, especially when the treatment 
involves hospitalization. A CT that is an example of treatment with hospitalization is the 
one conducted in paediatric patients. This CT’s data was particularly tough to report, since 
in hospitalization, the clinical diary is updated several times a day, and the information 
may be disperse and difficult to summarise, or the required data may be difficult to 
identify. Thus, the strategy I developed was to compile the information that was already 
reported, and compare it with the data that was being reported, in order to reduce 
discrepancies or repetition of data. If needed, a clarification could be requested to the 
responsible for that data record. This increased my organisation for that CT and the 
following activities I performed. 
Regarding the training I acquired at IPO-Porto, there are some activities in which I 
could not participate in, due to the organisation and specific rules of the institution. As 
explained in specific sections of the Regulatory Affairs (sections 2.1.1.2 and 2.1.1.3), I did 
not participate in these activities because they are not performed by SCs at UIC, even 
though I had a global idea of the general activities.  
Concerning the specific training, I did not have the opportunity to participate in close-
out visits, since they are only occur once. A close-out visit occurs when the CT ends (no 
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patients left to be followed) or due to early termination of CT. This visit has the objectives 
of solving open questions on data (e-CRF, queries, SAE report, clarifications, and notes-
to-file); ensuring all documents are up-to-date, complete, and archived; handling the 
remaining IMP and trial materials; and ensuring fee payments are correct and complete 
(58). When a CT ends, it has to be ensured that all documents are archived and can be 
consulted if necessary. 
In addition, I did not have the opportunity to participate in Investigators Meetings. The 
Investigators Meeting is attended by all the Investigators participating in the CT, and by 
SCs and or Study Nurses—as a trainee, I could not participate. This meeting provides 
training in the IMP and the CT, and is conducted before the CT begins. Its objectives are 
to ensure all staff receives the same information; provide specific training in the 
therapeutic area, the protocol and CRF; enable the staff to have an open discussion 
concerning the CT challenges and best practices; and provides a better view of all work 
and staff involved in the CT (59). 
Regarding Quality Management in Study Coordination, a SC has to ensure that all 
information is recorded and accurate, and that there is compliance with the protocol. For 
this matter, and whenever data is not properly recorded in the PHR, I would list the 
missing/inconsistent data and ask the responsible to correct or record the data in the 
PHR. Furthermore, quality is maintained through the performance of periodic internal 
audits. However, I did not have the opportunity to participate in one of those audits, due to 
the UIC’s organisation. When there is an audit, and depending on the findings, a 
Corrective Action and Preventive Action Plan may be implemented. 
Concerning the construction of documents at UIC, I have been given the opportunity to 
construct standard operating procedures for the pre-screening, screening, randomisation, 
and study termination, at IPO-Porto. These documents were constructed in the last month 
of my traineeship (June). These tasks allowed me to practice my medical writing skills and 
to contribute to the improvement of quality in clinical research at UIC.  
UIC has a very well organised and defined structure. During my traineeship, I 
identified several types of professional relationships in a SC’s daily routine.  
The SC’s relationship with the patient is very important, as aforementioned, since they 
may have significant doubts, and the SC may help. Furthermore, Oncology patients are 
usually overcoming a difficult phase of their lives. Thus, the SC should have the proper 
sensitivity while contacting with the patient. 
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Working with several Pathology Clinics allowed me to learn from different 
professionals and create my own perspective of the professional I aspire to be. A good 
professional relationship between the SC and the CT team, especially with the 
Investigators, strongly contributes for the success of a CT. 
From my experience, working with Urology CTs is rewarding, in the sense that the 
team is very motivated and organised, with strong support from the study nurses (who 
also complete CRFs for some CTs of this Pathology Clinic), and the tasks that were 
assigned to each member of the team were fulfilled in a cooperative manner. Support 
from the study nurses’ team is very important for the success of the CT and 
accompanying of the patient in the beginning of each treatment cycle. The study nurse 
gives any needed information and clarifies patients’ doubts, before the procedures. Since 
the SC has several CTs to attend to, and may not be present when the patient arrives to 
the institution (because the patients may arrive before the SC’s working hours), the Study 
Nurses’ support is a good advantage in this Pathology Clinic. 
Lung CTs were an opportunity for me to learn and grow as a professional. I learned a 
lot from these CTs, since the Pathology Clinic of Lung asked for the SC’s presence more 
often. Lung CTs demand more procedures than other CTs, what can be challenging. 
Thus, I had the opportunity to go to this clinic frequently, and observe its functioning. The 
Pathology Clinic of Lung is different from the Urology Clinic, essentially in the support from 
the Study Nurses’ team. Thus, the SC has to give more support to the CT team, and the 
Investigators do not have the same support as in the Pathology Clinic of Lung. Also, to 
improve the Pathology Clinic’s performance and strengthen the staff’s engagement, a 
strategy that is being developed is the compilation of all Lung CTs’ criteria and summaries 
of the protocol to support the Investigators.  
In the context of working with professionals from another institution, I acknowledged 
that the relationship between the SC and the CRA is very important in order to achieve a 
supportive teamwork, for example concerning the e-CRF completion and when there are 
any doubts or a strict deadline to meet (such as an interim analysis). It is important to 
focus that, although they are professionals from different institutions, the SC and the CRA 
have to work together to comply with the protocol and GCP. 
In addition, an issue that was part of most of my working days was communication 
with Data Managers/Medical Managers, through e-CRF completion. While completing e-
CRFs and answering to queries, I would sometimes describe the interaction between the 
SC and data manager as a “Ping-Pong game”. In some situations, this interaction may be 
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difficult, since the Data Manager/Medical Manager does not have access to source 
documents. If there is any discrepancy, the Data Manager/Medical Manager generates a 
query that is answered by the SC. Sometimes, the answer may not be satisfactory, and 
the query has to be clarified. It is important to provide all information clearly and concisely, 
by both professionals, to solve the query as soon as possible.  
In relation to all this thoughts, I consider that cooperation and team spirit are 
determinant factors for the success of any multidisciplinary team that wants to achieve a 
common goal—especially in a healthcare institution. 
 
3.1.1. Special and vulnerable populations specificities 
As stated in section 1.3.4, special/vulnerable populations participate in Oncology CTs, 
and require distinctive attention. Since I was enrolled in Oncology CTs, I dealt with 
representatives of such populations (children, in Paediatrics; elderly in Lung and Urology; 
vulnerable subjects, in Intensive Care).  
I identified some potential difficulties related with special populations, regarding ICFs 
signature. For example, geriatric patients may have difficulties writing their name in the 
ICFs. Thus, it has to be written in the PHR that, although the patient was able to sign the 
ICFs, he/she was not able to write the full name or the name with capital letter. Having an 
accompanying person during this visit is important, to help the patient understanding the 
document. Furthermore, elderly or non-instructed patients may have some concerns 
about the CT, regarding the study procedures and the need to do additional exams that 
they would not perform according to the clinical practice. Other issues may be related with 
the Investigator opinion. This is, the patient may have the need to ask directly if the 
Investigator considers the IMP a better option. According to GCP, the Investigator should 
not influence the patient’s decision. For this reason, the Investigator should clarify some 
considerations about the CT in general, and clarify specific doubts related with the IMP 
and the need to perform additional tests and doctor appointments, but not give a personal 
opinion. 
Regarding paediatric patients, they are not legally able to provide consent. The people 
responsible for their participation in a CT are their parents/legal guardian (34, 60). Thus, 
the ICF is signed by the responsible person. The Investigator should explain the CT to the 
minor in terms he/she can understand, and obtain his/her assent, when possible (34, 60). 
Concerning the CT MK0517-029, patients of appropriate intellectual maturity and able to 
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write their names, should sign the written assent form, which is a separate document, if 
they agree to participate in the CT.  
Patients unable to give consent are considered vulnerable, since they depend on other 
person’s decision (35). As an example, the INHALE 2 CT was specifically indicated to 
intubated and mechanically-ventilated patients with gram-negative pneumonia (56, 57). 
Thus, it was pointed out by the PI that obtaining the patients’ consent would be a 
significant difficulty, since they would be bedridden and debilitated. If the patient is unable 
to provide oral consent, the legally acceptable representative should be the one to decide 
if the patient participates in the study, and give his/her consent (35). If the patient is able 
to give his/her oral consent, an impartial witness should be present during the ICF 
discussion. The witness should sign and date the ICF, attesting that the patient has been 
explained the ICF and apparently understood its information (35). The witness also attests 
that the patient freely gave his/her consent (35). During the period of my traineeship, no 
patients were randomised for this CT, and I have not experienced this situation. In this CT, 
there was a screening failure at the centre, during the weekend. I was not able to attend 
this appointment, since UIC is closed at weekends. 
 
3.2. TRENDS IN EUROPEAN AND PORTUGUESE CLINICAL TRIALS 
The number of CTs in the European Union, dropped 25% between 2007 and 2011 
(61). The Directive 2001/20/EC fostered the decline in clinical trial activity in the European 
Union, due to the R&D expenditure, CTs’ feasibility, recruitment targets and non-
harmonised rules for multinational CTs (61, 62). A new regulation on CTs has been 
published in May 2014 (63), in an attempt to facilitate the conduct of multinational CTs. 
The scope of the “Regulation (EU) No 536/2014 of the European Parliament and of the 
Council of 16 April 2014 on clinical trials on medicinal products for human use, and 
repealing Directive 2001/20/EC” encompasses all CTs conducted in the European Union 
(63).  
The new regulation defines new considerations in what concerns the approval of CTs 
from each Member State: a single notification with the CT authorisation or refusal will be 
issued by the Member State (63). This may have consequences for the CT approval 
process in Portugal, since three approvals are needed to initiate a CT (INFARMED, CEIC 
and CNPD). This regulation will come into effect in 28 May 2016 (63), and may be a good 
contribute for the improvement of bottlenecks in the conduction of CTs. Initiatives such as 
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IMI2 (18) also reveal an effort of improving the sector and bring innovative developments 
to provide better healthcare to individuals. 
Regarding CTs in Portugal, its number is still reduced (9). PricewaterhouseCoopers 
International Limited has published a report on CTs in Portugal, in 2013, that describes 
specific challenges of CTs’ conduction in Portugal (9). According to the report, CTs’ 
reputation is negative; clinical research is not considered strategic for national economy; 
there is a lack of “clinical research culture”; the investigators are not properly recognised 
for their work; a few number of healthcare units are alert for clinical research; and there is 
lack of academic knowledge on CTs.  
In addition, the report identifies issues that have been recently addresses in the new 
aforementioned Portuguese legislation on CTs (37): the deadlines for CTs’ approval have 
not been competitive until now; there has not existed specific regulation regarding CTs’ 
disclosure; and a platform for CTs’ disclosure was lacking. These particular issues have 
been addressed, as proposed by the report, by the new Portuguese CTs’ legislation, 
which has established competitive dealines for CTs’ approval (as presented in section 
2.1.1.1); established considerations about CTs’ disclosure, and the National Registry of 
CTs to allow public disclosure of the national clinical research. 
With the changes in the Portuguese legislation, we have started to address the 
bottlenecks that are critical in Portugal. The aforementioned report on CTs in Portugal 
proposes strategies to aid this process, such as the development of an independent 
organisation dedicated to clinical research; a national health education and CTs’ 
disclosure strategy; and incentives to the inclusion of clinical research in professional 
careers.  
As an institution with a well-established clinical research unit, IPO-Porto has shown a 
sustained number of patients recruited to its CTs, what is an example of the Portuguese 
potential of increasing the number of CTs and increase the clinical research in Portugal. 
Hopefully, more improvements will be made in Portugal, in order to foster clinical research 
and bring more CTs to the country. 
 
3.2.1. Transparency in Clinical Trials 
A topic that I consider important, and that is now starting to be addressed more 
seriously, is the need for transparency in CTs. Society has gained awareness on the need 
of generating clear evidence that supports a medicinal product’s added value. An example 
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of an initiative developed to increase the transparency through registries is the “AllTrials 
campaign” (64). This global campaign defends that the results of CTs should be available 
to doctors and regulators, so that they can make informed decisions about treatments. 
Thus, the aim of the campaign is to make all evidence about a given treatment available, 
even the ones with negative results, so that its risks can be better understood (64). As 
another example, the EMA has published a draft policy on publication and access to 
clinical-trial data, to be adopted by the Board in July 2014. The debate on transparency 
through registries is still on, and the companies, Sponsors, and all stakeholders have 
already started to decide whether to be in favour or against these initiatives. 
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4. Conclusions 
The traineeship experience at UIC was very useful to link the knowledge acquired in 
the Bachelor’s in Biomedical Sciences and Master’s in Pharmaceutical Medicine degrees 
with the work marketplace. I could put the knowledge I already had in practice, and 
complement it with a new perspective—on-the-job. Particularly, I solidified and/or 
remembered the knowledge in anatomy, GCP, clinical drug development and the drug life 
cycle, medicines regulation, psychology of communication, and ethics in clinical research.  
Regarding specific activities, the development of Standard Operating Procedures and 
the medical writing skills I acquired, both during the academic training, were very useful 
for the development of Procedures for pre-screening, screening, randomisation/treatment 
initiation and study termination, at IPO-Porto. Besides, the Problem Based Learning 
method used in the Bachelor’s degree, and the solid critical thinking skills I acquired from 
my academic background strongly contributed for the accomplishment of several activities 
during my traineeship. In addition, the participation in a study developed by the Clinical 
Research Office of the Health Sciences Department allowed me to have an idea of the 
patients’ opinions and perceptions of clinical research, before starting the traineeship. This 
was helpful to understand the patients’ needs, in terms of information and the level of 
detail and literacy that should be used while communication with each patient.  
During the traineeship, I understood the SC’s role in CTs conduction: It is a crucial 
role, functioning as a contact point between the Investigators, CT team, and the Sponsor. 
The SC has an active role, particularly in ensuring compliance with the protocol and GCP, 
problem solving, and keeping an appropriate record of data related with the CT, what can 
be very challenging. When I understood the study coordination reality, I acknowledged 
that the SC’s role in CTs conduction may be determinant to its success. I also understood 
that at IPO-Porto, Study Coordination is restricted to the CT conduction after its approval, 
since this is a well organised study site, and UIC has well defined roles for each 
professional, due to its sustained growth since 2006. However, usually, Study 
Coordinators also cumulates regulatory affairs activities. I also would like to contribute to 
the activities that occur before and after CT conduction in a research site, to complete my 
experience. 
The SC’s day is never a routine: there are always new issues to address or follow-up, 
and many unforeseen issues and interruptions may occur. Thus, completing all tasks that 
were expected for the day may be difficult and requires strong time management skills 
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and focus. I had to find time to solve any problems that may occur, or urgent situations, 
such as an SAE to report. The priorities for the day may change, and a SC needs a good 
ability to make quick decisions and sound prioritisation, as well as strong communication 
skills.  
As my traineeship evolved, I engaged more activities and responsibilities, which 
helped me to grow and develop communication skills and ability to focus. I verified that 
meeting the team and professionals allowed me to gain trust and participate more actively 
in discussions and give my opinion. Feeling part of the team helped a lot, and I can say 
that this experience will, for sure, help my future professional relationships. 
During this traineeship, I was able to meet my primary objectives, regarding study 
coordination skills, and the reinforcement of my background knowledge, both from the 
BSc and MSc. The opportunity to participate in the coordination of 15 CTs in different 
areas of Oncology was a great approach to train a broad range of the study coordination 
activities. Being part of a team such as UIC permitted me to have a perspective of the 
working environment and understand the functioning of an organised and recognised 
clinical research centre. 
Regarding the secondary objectives, I met most of the challenges. However, many of 
the Study Coordination activities I performed were observational, and some of them on-
the-job. For example, I was present during several patients’ study visits, but did not 
interact directly with them, and interacted with Investigators a few number of times. 
Although this was very useful to understand the communications’ flow in a clinical 
research centre and to improve my communicational skills, it could have been beneficial 
to have the experience of speaking directly to the patients and explain the procedures or 
clarify any doubts. However, since I was performing other study coordination activities, it 
would have been difficult to be prepared to this situation without previous study and 
preparation, and this was not possible due to the organisation of UIC. Due to these visits 
to clinics, I understood the route of the PHR of the CTs’ patients, which was a secondary 
objective. In addition, the development of internal procedures at IPO-Porto allowed me to 
understand its relevance for the quality of a clinical research centre. I acknowledged that 
quality assurance and GCP compliance are areas of personal interest for me, in which I 
would like to contribute to, more actively, in the future. I also would like to be involved in 
the conduction and/or preparation of an audit, to complement my training. I acknowledged 
that I would like to continue contributing for the quality of clinical research, as a 
professional of CTs.  
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